Jürg Reichen - List of publications#

Original Publications

1. Reichen J, Paumgartner G (1975). Kinetics of taurocholate uptake by the perfused rat liver. Gastroenterology 68: 132-136.

2. Paumgartner G, Reichen J (1975). Different pathways for hepatic uptake of indocyanine green and taurocholate. Experientia 31: 306-307.

3. Reichen J, Paumgartner G (1976). Uptake of bile acids by the perfused rat liver. Am J Physiol 231: 734-742.

4. Paumgartner G, Reichen J (1976). Kinetics of hepatocellular uptake of unconjugated bilirubin. Clin Sci Mol Med 51: 169-176.

5. Reichen J, Paumgartner G (1977). Relationship between bile flow and Na,K-adenosine triphosphatase in liver plasma membranes enriched in bile canaliculi. J Clin Invest 60: 429-434.

6. Klos C, Paumgartner G, Reichen J (1979). Cation-anion gap and choleretic properties of rat bile. Am J Physiol 236: E434-E440.

7. Reichen J, Paumgartner G (1979). Inhibition of hepatic Na,K-adenosine triphosphatase in taurolithocholate-induced cholestasis in the rat. Experientia 35: 1186-1188.

8. Reichen J, Berk PD (1979). Isolation of an organic anion binding protein from rat liver plasma membrane fractions by affinity chromatography. Biochem Biophys Res Comm 91: 484-489.

9. Paumgartner G, Vasella DL, Herz R, Reichen J, Preisig R (1979). Hepatic extraction of taurocholate and indocyanine green in patients with liver disease. Z Gastroenterol 17: 753-761.

10. Reichen J, Paumgartner G, Berk PD, Paumgartner D (1979). Effects of bile acids on enzymes of the canalicular membrane and on protein excretion into bile. In "Biological Effects of Bile Salts", G Paumgartner and A Stiehl, editors. MTP Press Ltd. Lancaster 1979, pp 25-26.

11. Reichen J, Berk PD (1980). The role of liver plasma membrane proteins on the transport of organic anionic dyes. In "Communications of Liver Cells", H Popper, L Bianchi, F Gudat and W Reutter, editors. MTP Press Ltd., Lancaster 1980, pp 59-67.

12. Reichen J, Blitzer BL, Berk PD (1981). Binding of unconjugated and conjugated sulfobromophthalein to rat liver plasma membrane fractions in vitro. Biochim Biophys Acta 640: 298-312.

13. Reichen J, Berman MD, Berk PD (1981). The role of microfilaments and microtubules in taurocholate uptake by isolated rat liver cells. Biochim Biophys Acta 643: 126-133.

14. Reichen J, Hoilien C, Sheldon GF, Kirshenbaum G (1983). A novel method for continuous monitoring of bilirubin production in unstressed rats. Am J Physiol 244: G336-G340.

15. Reichen J, Le M (1983). Taurocholate, but not taurodehydrocholate increases biliary permeability to sucrose. Am J Physiol 245: G651- G655.

16. Reichen J, Le M (1984). Influence of common bile duct cannular size on maximal secretory rate of taurocholate in the rat. Experientia 40: 535-537.

17. Berr F, Simon FR, Reichen J (1984). Ethynyl estradiol impairs tauro­cholate transport and Na,K pump in isolated hepatocytes. Am J Physiol 247: G437-G443.

18. Berry WR, Kirshenbaum G, Hoilien C, Le M, Reichen J (1985). Taurolithocholate increases heme catabolism and alters the clearance of antipyrine in the rat. Gastroenterology 88: 397-402.

19. Finck MH, Reichen J, Vierling JM, Kloppel TM, Brown WR (1985). Hepatic uptake and disposition of human polymeric IgA in the perfused rat liver: Evidence for incomplete biliary excretion and intrahepatic degradation. Am J Physiol 248: G450-G455.

20. Reichen J, Berr F, Le M, Warren GH (1985). Characterization of calcium deprivation induced cholestasis in the perfused rat liver. Am J Physiol 249: G48-G57.

21. Fritzberg A, Reichen J (1985). Extraction efficiency and biliary excretion of hepatobiliary imaging agents in the rat perfused liver. J Pharm Pharmac 37: 919-922.

22. Meister F, Reichen J (1986). Quantitative liver function tests in por­phyria cutanea tarda: Improvement during phlebotomy. Schweiz Med Wschr. 116: 341-345.

23. Reichen J, Krähenbühl S, Küpfer A, Sägesser H, Karlaganis G (1986). Defective bile acid transport in an animal model of defective debriso­quine hydroxylation. Biochem Pharmacol 35: 753-759.

24. Reichen J, Hirlinger A, Ha HR, Sägesser H (1986). Chronic verapamil administration lowers portal pressure and improves hepatic function in rats with liver cirrhosis. J Hepatol 3: 49-58.

25. Reichen J, Hoilien C, Kirshenbaum G (1986). Cimetidine induces hepatic heme oxygenase without altering hepatic heme catabolism. Experientia 42: 942-945.

26. Reichen J, Le M (1986). Verapamil favourably influences hepatic microvascular exchange and function in rats with cirrhosis of the liver. J Clin Invest 78: 448-455.

27. Kloppel TM, Brown WR, Reichen J (1986). Mechanism of secretion of proteins into bile. Studies in the perfused rat liver. Hepatology 6: 587-594.

28. Kloppel TM, Brown WR, Reichen J (1986). Effects of monensin on vesicular pathways in the perfused rat liver. J Cell Biochem 32: 235-245.

29. Reichen J, Hoilien C, Le M, Jones RH (1987). Decreased uptake of taurocholate and of ouabain by hepatocytes isolated from cirrhotic rat liver. Hepatology 7: 67-70.

30. Gross JB Jr., Reichen J, Zeltner TB, Zimmermann A (1987). The evolution of changes in quantitative liver function tests in a rat model of biliary cirrhosis: Correlation with morphometric measurement of hepatocyte mass. Hepatology 7: 457-463.

31. Reichen J, Karlaganis G, Kern F, Jr. (1987). Bile acid synthesis in pregnant hamster. Proceedings of the Falk Symposium 45, Bile Acids and the Liver. G. Paumgartner, A. Stiehl and W. Gerok, eds., MTP Press, Lancaster, pp 65-72.

32. Reichen J, Arts B, Schafroth U, Zimmermann A, Zeltner TB, Zysset T (1987). Aminopyrine N-demethylation by rats with liver cirrhosis: Evidence for the intact cell hypothesis. A morphometric-functional study. Gastroenterology, 93: 719-726.

33. Reichen J, Karlaganis G, Kern F, Jr. (1987). Cholesterol synthesis in the perfused liver of pregnant hamsters. J Lipid Res, 28: 1046-1052.

34. Reichen, J, Saegesser, H (1988). The role of the hepatic artery in canalicular bile formation by the perfused rat liver. A multiple indicator dilution study. J Clin Invest, 81: 1462-1469.

35. Jordi-Racine, AL, Alvarez E, Reichen J (1988). The effect of hypoxia on hepatic cytochromes and heme turnover in rats in vivo. Experientia, 44: 343-345.

36. Navasa M, Bosch J, Reichen J, Bru C, Mastai R, Zysset T, Silva G, Chesta J, Rodes J (1988). Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension, Hepatology, 8: 850-854.

37. Krähenbühl S, Reichen J (1988). Canalicular bile flow and bile salt secretion are maintained in rats with liver cirrhosis: Further evidence for the intact cell hypothesis. J Hepatol, 7: 63-71.

38. Speich R, Saesseli B; Hoffmann U, Neftel KA, Reichen J (1988). Ana­phylactoid reactions after indocyanine green administration. Ann Int Med, 109: 345-346.

39. Everson GTE, Scherzinger A, Berger-Leff N, Reichen J, Lezotte D, Manco-Johnson M, Gabow P (1988). Polycystic liver disease: Quantitation of parenchymal and cyst volumes from TC images and clinical correlates of hepatic cysts. Hepatology, 8: 1627-1634.

40. Reichen J, Egger B, Ohara N, Zeltner TB, Zysset T, Zimmermann A (1988). Determinants of hepatic functions in liver cirrhosis in the rat: A multivariate analysis. J Clin Invest, 82: 2069-2076.

41. Cotting J, Reichen J (1989). Bile salts and hydrodynamics of bile formation. J Hepatol, 8: 13-21.

42. Reichen J, Le R (1989). Expansion of the bile acid pool changes the biliary transport characteristics of centrizonal hepatocytes. Experientia, 45: 135-137.

43. Cotting J, Zysset T, Reichen J (1989). Biliary obstruction in the rat dissipates the bioelectrical sinusoidal-canalicular barrier without altering taurocholate uptake. Am J Physiol, 256: G312-G318.

44. Krähenbühl S, Stucki J, Reichen J (1989). Mitochondrial function in carbon-tetrachloride-induced cirrhosis in the rat: Qualitative and quantitative defects. Biochem Pharmacol, 38: 1583-1588.

45. Oehler R, Reichen J, Zysset T, Bradley SE (1989). Non-micelle forming bile acids increase biliary gentamicin excretion in the rat. J Pharm Sci, 78: 648-651.

46. Terrier F, Vock P, Cotting J, Ladebeck R, Reichen J, Hentschel D (1989). Effect of i.v. fructose on the 31p-MR spectrum of the liver: Dose response in healthy volunteers. Radiology, 171: 557-563.

47. Knuchel J, Krähenbühl S, Zimmermann A, Reichen J (1989). Evidence for ductular secretion of bile in rats with cirrhosis of the liver: Structure-function relationship. Gastroenterology, 97: 950-957.

48. Krähenbühl S, Meier-Abt PJ, Reichen J (1989). Taurocholate transport by liver plasma membrane vesicles is not altered in cirrhotic rats. J Hepatol, 9: 1-9.

49. Caflisch C, Zimmerli B, Reichen J and Meier PJ (1990). Cholate uptake in basolateral rat liver plasma membrane vesicles and in liposomes. Biochim Biophys Acta 1021:70-76.

50. Cotting J, Zeugin T, Steiger U and Reichen J (1990). Albendazole kinetics in echinococcosis patients: Delayed absorption and impaired elimination in cholestasis. Eur J Clin Pharmacol 38:605-608.

51. Steiger U, Cotting J and Reichen J (1990). Albendazole treatment of echinococcosis in man: Effects on microsomal metabolism and drug tolerance. Clin Pharmacol Ther 47: 347-353.

52. Stammler L, Reichen J, Oehler R, Bianchi L, Landmann L (1990). Decreased hepatocellular volume and intact morphology of tight junctions in calcium deprivation-induced cholestasis. Stereological and multiple indicator dilution analysis. J Hepatol 10: 318-326.

53. Cotting J, Reichen J, Kutz K, Laplanche R, Nüesch E (1990). Pharmacokinetics of isradipine in patients with chronic liver disease. Eur J Clin Pharmacol 38:599-603.

54. Buters, TJM, and Reichen J (1990). Sex difference in antipyrine 3-hydroxylation. An in vivo - in vitro correlation of antipyrine metabolism in two rat strains. Biochem Pharmacol 40: 771-777.

55. Cotting J, Lentze MJ, Reichen J (1990). Effects of ursodeoxycholic acid treatment on nutrition and liver function in patients with cystic fibrosis and long-standing cholestasis. Gut 31: 918-921.

56. Krähenbühl S, Reichen J, Zimmermann A, Gehr P and Stucki J (1990). Mitochondrial structure and function in CCl4-induced cirrhosis in the rat. Hepatology 12: 526-532.

57. Roos FJ, Zysset T and Reichen J (1991). Differential effect of biliary and micronodular cirrhosis on oxidative drug metabolism: in vivo - in vitro correlations of dextrometorphan metabolism in rat models. Biochem Pharmacol 41: 1513-1519.

58. Aebli N, Reichen J (1991). Prognostic significance of serial determination of galactose elimination capacity in chronic active hepatitis. Schweiz Med Wschr 121: 970-976.

59. Gerbes A, Kollenda MC, Vollmar AM, Reichen J, Vakil N, Scarborough RM (1991). Altered density of glomerular binding sites for atrial natriuretic factor in bile duct-ligated rats with ascites. Hepatology 13: 562-566.

60. Dueland S, Reichen J, Everson GT and Davis RA (1991). Regulation of cholesterol and bile acid homeostasis in bile obstructed rats. Biochem J 280: 373-377.

61. Reichen J, Widmer T and Cotting J (1991). Accurate prediction of death by serial determinations of the galactose elimination capacity in primary biliary cirrhosis - A comparison with the Mayo model. Hepatology, 14: 504-510.

62. Reichen J, Buters JTM, Sojcic Z, and Roos FJ (1992)., Abnormal lipid composition of microsomes from cirrhotic rat liver - Does it contribute to decreased microsomal function? Experientia 48: 482-486.

63. Dufour JF, Stoupis C, Lazeyras F, Vock P, Terrier F and Reichen J (1992). Alterations in hepatic fructose metabolism in cirrhotic patients demonstrated by dynamic P-31 spectroscopy. Hepatology 15:835-842.

64. Zimmermann H, Reichen J, Zimmermann A, Sägesser H, Thenisch B and Höflin F (1992). Reversibility of secondary biliary fibrosis by biliodigestive anastomosis in the rat. Effect of relief of biliary obstruction on microsomal function, microsomal lipids, portal pressure and hepatic structure. Gastroenterology 103: 579-589.

65. Oguey D, Kölliker F, Gerber NJ and Reichen J (1992). Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis. Arthr Rheum 35:611-614.

66. Krähenbühl S, Stucki J and Reichen J (1992). Reduced activity of the electron transport chain in liver mitochondria isolated from rats with secondary biliary cirrhosis. Hepatology 15:1160-1166.

67. Krähenbühl S, Krähenbühl-Glauser S, Stucki J, Gehr P and Reichen J (1992). Stereological and functional analysis of liver mitochondria from rats with secondary biliary cirrhosis: Impaired mitochondrial metabolism and increased mitochondrial content per hepatocyte. Hepatology 15:1167-1172.

68. Dufour JF, Gehr P, Reichen J (1992). Hepatic accumulation of lysosomes and defective transcytotic pathways in cirrhotic rat liver. Hepatology, 16:997-1006.

69. Oguey D, Marti U, Reichen J (1992). Epidermal growth factor receptor in chronic bile duct obstructed rats: Implications for maintenance of hepatocellular mass. Eur J Cell Biol 59: 187-195.

70. Zimmermann H, Reichen J (1992). Ursodeoxycholate has no beneficial effect on liver function or histology in biliary cirrhosis in the rat. J Hepatol 16:355-359.

71. Ohara N, Schaffner T and Reichen J (1993). Structure - function relationship in secondary biliary cirrhosis in the rat: Stereologic and hemodynamic characterization of a model. J Hepatol 17:155-162.

72. Krähenbühl S, Reichen J (1993). Decreased hepatic glucose production in rats with carbon tetrachloride-induced liver cirrhosis. J Hepatol, 19:64-70.

73. Zimmermann H, Reichen J, Sägesser H, Thenisch B and Zimmermann A (1993). Biliary retention in a chronic choledocho-venous fistula in the rat: Induction of portal hypertension but not of biliary cirrhosis. J Hepatol, 19:110-116.

74. Giger A, Reichen J (1993). Die Leberbiopsie beim ambulanten Patienten. Diagnostische Wertigkeit im Vergleich zu konventionellen und quantitativen Leberfunktionsprüfungen. Schweiz. Med. Wschr. 123:1474-1481.

75. Buters JTM, Zysset T, Reichen J (1993). Metabolism of antipyrine in two rat models of liver cirrhosis: Its relationship to intrinsic clearance in vitro and microsomal membrane lipid composition. Biochem Pharmacol. 46:983-992.

76. Krähenbühl S, Grass P, Surve A, Kutz K and Reichen J (1993). Pharmacodynamics, pharmacokinetics, and tolerability of the novel ACE-inhibitor spirapril in patients with chronic liver disease. Eur J Clin Pharmacol. 45:247-254.

77. Reichen J, Solioz M, Bühler H, Gonvers JJ, Knoblauch M, Lavanchy D, Malé JP, Meyer B, Schmid M, Bianchi L (1993). Low dose interferon in chronic hepatitis NonA, NonB. Effects on quantitative liver function and structure in a multicenter, randomized, controlled trial. Clin Invest 71:888-893.

78. Widler P, Fisch H.U., Schoch P, Zimmermann A, Schläpfer TE, Reichen J (1993). Increased benzodiazepine-like activity is neither necessary nor sufficient to explain acute encephalopathy in the rat. Hepatology 18:1459-1464.

79. Krähenbühl S, Talos C, Fischer S, Reichen J (1994). Toxicity of bile acids on the electron transport chain of isolated rat liver mitochondria. Hepatology 19:471-479.

80. Reichen J, Bianchi L, Frei PC, Malé PJ, Lavanchy D, Schmid M and SASL (1994). Efficacy of steroid withdrawal and low dose interferon treatment in chronic active hepatitis B. Results of a randomized multicenter trial. J Hepatol, 20:168-174.

81. Zimmermann H, Blaser H, Zimmermann A, Reichen J (1994). Effect of development on the functional and histologic changes induced by bile duct ligation in the rat. J Hepatol 20: 231-239.

82. Dufour JF, Zimmermann A, Reichen J (1994). Increased hepatic lysosomal activity in biliary cirrhosis originates from hepatocytes rather than from macrophages. J Hepatol: 20 524-530.

83. Krähenbühl S, Talos C, Reichen J (1994). Mechanisms of impaired hepatic fatty acid metabolism in rats with long-term bile duct ligation. Hepatology 19: 1272-1281.

84. Lebbe C, Beyeler C, Gerber NJ, Reichen J (1994). Intraindividual variability of the bioavailability of low dose methotrexate after oral administration in rheumatoid arthritis. Arthr Rheum Dis 53: 475-477.

85. Gebhardt R, Reichen J (1994). Changes in distribution and activity of glutamine synthetase in carbon tetrachloride-induced cirrhosis in the rat: Potential role in hyperammonemia. Hepatology 20: 684-691.

86. Elsing C, Sägesser H, Reichen J (1994). Ursodeoxycholate-induced hypercholeresis in cirrhotic rats: Further evidence for cholehepatic shunting. Hepatology 20: 1048-1054.

87. Elsing C, Reichen J, Marti U, Renner EL (1994). Hepatocellular Na+/H+-exchange is activated at the transcriptional and posttranscriptional levels in biliary cirrhosis in the rat. Gastroenterology 107:468-478.

88. Seiler CA, Renner EL, Horber F, Rieder H, Reichen J, Czerniak A (1994). Can a small liver transplant program compare with the international standard? Results at Inselspital Berne. Schweiz. Med. Wochenschr. 124: 2123-2130

89. Oguey D, Marti U, Reichen J (1994). Differential effect of micronodular and biliary cirrhosis on epidermal growth factor receptor expression in the rat. J Hepatol 21: 997-1005.

90. Krähenbühl S, Fischer S, Talos C, Reichen J (1994). Ursodeoxycholate protects oxidative mitochondrial metabolism from bile acid toxicity: Dose-response study in isolated rat liver mitochondria. Hepatology 20: 1595-1601.

91. Elsing C, Hirlinger A, Renner EL, Lauterburg BH, Meier PJ, Reichen J (1995). Solvent isotope effects on bile formation in the rat. Biochem J 307:175-181.

92. Krähenbühl S, Talos C, Lauterburg BH, Reichen J (1995). Reduced antioxidative capacity in liver mitochondria from bile duct ligated rats. Hepatology 22: 607-612.

93. Zimmermann H, Ganz P, Zimmermann A, Oguey D, Marti U, Reichen J (1995) The overexpression of proliferating cell nuclear antigen in biliary cirrhosis in the rat and its relationship with epidermal growth factor receptor. J. Hepatol. 23:459-464.

94. Dällenbach A, Renner EL, Solioz M, Bianchi L, Schmid M, Reichen J (1995). Does serum HCV RNA positive differ from serum HCV RNA negative chronic hepatitis C? Comparison of morphological and functional findings. Schweiz.Med.Wochenschr. 125: 1855-1863.

95. Marti U, Elsing C, Renner EL, Liechti-Gallati S, Reichen J (1996). Differential expression of Na+,H+-antiporter mRNA in biliary epithelial cells and in hepatocytes. J Hepatol. 24:498-502.

96. Ballmer PE, Reichen J, McNurlan MA, Sterchi AB, Anderson SE, Garlick PJ (1996). Albumin but not fibrinogen synthesis correlates with galactose elimination capacity in patients with cirrhosis of the liver. Hepatology 24:53-59.

97. Vishwanath BS, Frey FJ, Escher G, Reichen J, Frey BM (1995). Liver cirrhosis induces renal and liver phospholipase A2 activity in rats. J. Clin. Invest 98: 365-371.

98. Forestier M, Reichen J, Solioz M (1996). Application of mRNA differential display to liver cirrhosis: Reduced fetuin expression in biliary cirrhosis in the rat. Biochem. Biophys. Res. Comm. 225: 377-383.

99. Reichen J, Bianchi L, Bühler H, Dolivo N, Gonvers JJ, Lavanchy D, Malé JP, Renner EL, Solioz M, Schmid M (1996). Fixed versus titrated interferon-a2b in chronic hepatitis C. A randomized controlled trial. J. Hepatol. 25: 275-282.

100. Krähenbühl L, Talos C, Reichen J, Krähenbühl S (1996). Progressive decrease in tissue glycogen content in rats with long-term cholestasis. Hepatology 24: 902-907.

101. Krähenbühl S, Reichen J (1996). Carnitine metabolism in patients with chronic liver disease. Hepatology 25: 148-153.

102. Krähenbühl L, Reichen J, Talos C, Krähenbühl S (1997). Benzoic acid metabolism reflects hepatic mitochondrial function in rats with long-term extrahepatic cholestasis. Hepatology 25:278-283.

103. Bustos Castillo M, Berchtold MW, Rülicke T, Schwaller B, Gotzos V, Pinzani M, Reichen J, Celio MR (1997). Ectopic expression of the calcium binding protein parvalbumin in mouse liver endothelial cells. Hepatology 25: 1154-1159.

104. Lebbe C, Reichen J, Wartna E, Sägesser H, Poelstra K, Meijer DKF (1997). Targeting naproxen to non-parenchymal liver cells protects against endotoxin induced liver damage. J Drug Targeting 4:303-310.

105. Vallée JP, Stoupis C, Hiltbrand E, Zimmermann H, Lazeyras F, Binzoni T, Howarth N, Zimmermann A, Reichen J (1997). Dynamic phosphorus-31 spectroscopy after fructose load in experimental biliary liver cirrhosis. Acad. Radiol. 4: 26-34.

106. Beyeler C, Reichen J, Thomann SR, Lauterburg BH, Gerber NJ (1997). Quantitative liver function in patients with rheumatoid arthritis treated with low-dose methotrexate: A longitudinal study. Br. J. Rheumatol. 36: 338-344.

107. Forestier M, Solioz M., Izbéki F, Talos C, Reichen J, Krähenbühl S (1997). Hepatic mitochondrial proliferation in rats with secondary biliary cirrhosis: Time course and mechanisms. Hepatology 26: 386-391.

108. Kleinle S, Wiesmann U, Superti-Fuga A, Krähenbühl S, Boltshauser E, Reichen J, Liechti-Gallati S (1997). Detection and characterization of mitochondrial DNA rearrangements in Pearson and Kearns-Sayre syndromes by long PCR. Human Genetics 100: 643-650.

109. Boesch C, Elsing C, Wegmüller H, Felblinger J, Vock P, Reichen J (1997). Effect of ethanol and fructose on liver metabolism: A dynamic 31Phosphorus magnetic resonance spectroscopy study in normal volunteers. Magnetic Resonance Imaging 15: 1067-1077.

110. Seiler CA, Renner EL, Schilling M, Rieder H, Reichen J, Bischoff P, Büchler MW (1997). Liver transplantation in small centers: Practicability, efficacy and perspectives. Chirurg 68: 1004-1010.

111. Albrecht C, Reichen J, Visser J, Meijer DKF, Thormann W (1997). Differentiation between naproxen, naproxen-protein conjugates, and naproxen-lysine in plasma via micellar electrokinetic capillary chromatography – a new approach in the bioanalysis of drug targeting preparations. Clin. Chem. 43: 2083-2090.

112. Albrecht C, Meijer DKF, Lebbe C, Sägesser H, Melgert BN, Poelstra K, Reichen J (1997). Targeting naproxen coupled to human serum albumin to nonparenchymal cells reduces endotoxin-induced mortality in rats with biliary cirrhosis. Hepatology, 26: 1553-1559.

113. Diamantis I, van de Casteele M, Hurni B, Reichen J (1998). Detection of endothelin-1 and its receptors in rat liver endothelial cells by in situ reverse transcriptase-polymerase chain reaction. J. Hepatol. 28: 157-160.

114. Escher G, Nawrocki A, Staub T, Vishwanath BS, Frey BM, Reichen J, Frey F (1998). Downregulation of hepatic and renal 11b-hydroxysteroid dehydrogenase in rats with liver cirrhosis. Gastroenterology 114: 175-184.

115. Reichen J, Gerbes AL, Steiner MJ, Sägesser H, Clozel M (1998). The effect of endothelin and its antagonist Bosentan on hemodynamics and microvascular exchange in cirrhotic rat liver. J. Hepatol. 28:1020-1030.

116. Stähelin BJ, Marti U, Solioz M, Zimmermann H, Reichen J (1998). False positive staining in the tunel assay to detect apoptosis in liver and intestine is due to endogenous nucleases and inhibited by diethyl pyrocarbonate. J. Clin. Pathol. Mol. Pathol. 51: 204-208.

117. Melgert BN, Wartna E, Lebbe C, Albrecht C, Molema G, Poelstra K, Reichen J, Meijer DKF (1998). Targeting of naproxen covalently linked to HSA to sinusoidal cell types of the liver. J Drug Target 5: 329-342.

118. Albrecht C, Melgert BN, Reichen J, Poelstra K, Meijer DKF (1998). Effect of chronic bile duct obstruction and LPS upon targeting of naproxen to the liver using naproxen-albumin conjugate. J Drug Target 6: 105-117.

119. Lahaye P, Fouassier L, Tazil KA, De Gottardi A, Fléjou JF, Chagneau C, Rona JP, Housset C, Reichen J, Lebrec D, Moreau R (1999). Endothelium-dependent blunted membrane potential responses to ATP-sensitive K+ channel modulators in aortae from rats with cirrhosis. J. Hepatol. 30: 107-114.

120. Stähelin BJ, Marti U, Zimmermann H, Reichen J (1999). The interaction of Bcl-2 and Bax regulates apoptosis in biliary epithelial cells of rats with obstructive jaundice. Virchows Arch 434: 333-339.

121. Poretti D, Felleisen E, Grimm F, Pfister M, Teuscher F, Zuercher C, Reichen J, Gottstein B (1999). Differential immunodiagnosis between cystic hydatid disease and other cross-reactive pathologies. Am. J. Trop. Med. Hyg. 60: 193-198.

122. Zimmermann A, Zhao D, Reichen J (1999). Myofibroblasts in the cirrhotic rat liver reflect hepatic remodeling and correlate with fibrosis and sinusoidal capillarization. J. Hepatol. 30: 646-652.

123. Zimmermann A, Zimmermann H, Fellay M, Reichen J (1999). Cells with morphological and immunohistochemical features of hepatic stellate cells (Ito cells) form an extralittoral (extrasinusoidal) compartment in the cirrhotic rat liver. Histol Histopathol 14: 719-727.

124. Ackermann D, Vogt B, Escher G, Dick B, Reichen J, Frey B, Frey FJ (1999). Inhibition of 11b-hydroxy steroid dehydrogenase by bile acids in rats with liver cirrhosis. Hepatology 30: 623-629.

125. Van de Casteele M, Hösli M, Sägesser H, Reichen J (1999). Intraportal administration of glyceryl trinitrate or nitroprusside in cirrhotic animals exerts more systemic than intrahepatic effects. J. Hepatol. 31:300-305.

126. Seiler CA, Dufour JF, Renner EL, Schilling M, Büchler MW, Bischoff P, Reichen J (1999). Primary liver disease as a determinant for acute rejection after liver transplantation. Langenbeck's Arch. Surg. 384: 259-263.

127. Kammer AR, van der Burg SH, Grabscheid B, Hunziker IP, Kwappenberg KMC, Reichen J, Melief CJM, Cerny A (1999). Molecular mimicry of human cytochrome P450 by hepatitis C virus at the level of cytotoxic T cell recognition. J. Exp. Med. 190: 169-176.

128. Diamantis I, Lüthi M, Hösli M, Reichen J (1999). Cloning of the rat ADAMTS1 gene. ADAMTS1 is down regulated in liver endotheliall cells in cirrhotic rats. Liver 20: 165-172.

129. Bissig KD, Marti U, Solioz M, Forestier M, Zimmermann H, Lüthi M, Reichen J (2000). Epidermal growth factor is decreased in rats with biliary cirrhosis but does not act as paracrine growth factor immediately after hepatectomy. J. Hepatol. 32: 275-281.

130. Cucchiarini M, Kammer AR, Grabscheid B, Diepolder HM, Gerlach TJ, Grüner N, Santantonio T, Reichen J, Pape GR, Cerny A (2000). Vigorous peripheral blood cytotoxic T cell response during the acute phase of hepatitis C virus infection. Cellular Immunol 203: 111-123.

131. De Gottardi A, Shaw S, Sägesser H and Reichen J (2000). Type A, but not type B, endothelin receptor antagonists significantly decrease portal pressure in portal hypertensive rats. J. Hepatol. 33: 733-737.

132. Zeuzem S, Feinman VS, Rasenack J, Lai MY, Gane E, O'Grady J, Reichen J, Diago M, Lin A, Hoffmann J, Brunda MJ (2000). Peginterferon alpha in patients with chronic hepatitis C. N. Engl. J. Med. 343: 1666-1672.

133. Tièche S, De Gottardi A, Kappeler A, Shaw S, Sägesser H, Zimmermann A, Reichen J (2001). Overexpression of endothelin-1 in bile duct ligated rats: Correlation with activation of hepatic stellate cells and portal pressure. J. Hepatol. 34: 46-52.

134. Issa R, Williams E, Trim N, Kendall T, Arthur MJP, Reichen J, Benyon RC, Iredale JP (2001). Apoptosis of hepatic stellate cells: Involvement in resolution of biliary fibrosis and regulation by soluble growth factors. Gut 48: 548-557.

135. Fattinger K, Funk C, Pantze M, Weber C, Reichen J, Stieger B, Meier PJ (2001). The endothelin antagonist Bosentan inhibits the canalicular bile salt export pump: A potential mechanism for hepatic adverse reactions. Clin Pharmacol Ther 69: 223-231.

136. Gottstein B, Saucy F, Deplazes P, Reichen J, Demierre G, Busato A, Zuercher C, Pugin P (2001). Is high prevalence of Echinococcus multilocularis in wild and domestic animals associated with disease incidence in humans? Emerging Inf Dis 7: 408-412.

137. Van Nunen AB, Baumann M, Manns MP, Reichen J, Spengler U, Marschner JP, de Man RA (2001). Efficacy and safety of an intravenous monoclonal anti-HBs in chronic hepatitis B patients. Liver 21: 207-212.

138. Van de Casteele M, Sägesser H, Zimmermann H, Reichen J (2001). Characterisation of portal hypertension models by microspheres in anaesthetised rats: a comparison of liver flow. Pharmacol Ther 90:35-43.

139. Redaelli CA, Dufour JF, Wagner M, Schilling M, Hüsler J, Krähenbühl L, Büchler MW, Reichen J (2001). Preoperative galactose elimination capacity predicts complications and survival after hepatic resection. Ann Surg 235: 77-85.

140. Spycher CA, Zimmermann A, Reichen J (2001). The diagnostic value of liver biopsy. BMC Gastroenterology 1:12 http://www.biomedcentral.com/1471-230X/1/12/.

141. Helbling B, Stamenic I, Viani F, Gonvers JJ, Dufour JF, Reichen J, Cathomas G, Steuerwald M, Borovicka J, Sagmeister M, Renner EL (2002). Interferon and amantadine in naïve chronic hepatitis C: A double-blind, randomized, placebo-controlled trial. Hepatology 35:447-454.

142. Schäfer M, Sägesser H, Reichen J, Krähenbühl L (2002). Alterations in haemodynamics and hepatic and splanchnic circulation during laparoscopy in rats. Surg Endoscopy 15: 1197-1201.

143. Dufour JF, Zimmermann M, Reichen J (2002). Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. J Hepatol 37: 748-752.

144. Stumm MM, D’Orazio D, Sumanovski LT, Martin PY, Reichen J, Sieber CC (2002). Endothelial, but not the inducible, nitric oxide synthase is detectable in normal and portal hypertensive rats. Liver 22: 441- 450.

145. Van de Casteele M, van Pelt JM, Nevens F, Fevery J, Reichen J (2003). Low NO bioavailability in cirrhotic rat livers might result from low NO synthesis combined with decreased superoxide dismutase activity allowing superoxide-mediated NO breakdown: A comparison of two portal hypertensive rat models with healthy controls. Comp Hepatol 2:2. http://www.comparative-hepatology.com/content/2/1/2.

146. Forestier M, Bänninger R, Reichen J, Solioz M (2003). Betaine Homocysteine Methyltransferase: Gene Cloning and Expression Analysis in Rat Liver Cirrhosis. Biochim Biophys Acta, 1638: 29-34.

147. Neef M, Biecker E, Heller J, Schepke M, Nischalke HD, Wolff M, Spengler U, Reichen J, Sauerbruch T (2003). Portal hypertension is associated with increased mRNA levels of vasopressor G-protein coupled receptors in human hepatic arteries. Eur J Clin Invest 33: 249-255.

148. Gremion C, Grabscheid B, Wolk B, Moradpour D, Reichen J, Pichler W, Cerny A (2004). Cytotoxic T lymphocytes derived from patients with chronic hepatitis C virus infection kill bystander cells via Fas-FasL interaction. J Virol 78: 2152-2157.

149. Biecker E, Neef M, Sägesser H, Shaw S, Koshy A, Reichen J (2004). Nitric oxide synthase 1 is partly compensating for nitric oxide synthase 3 deficiency in nitric oxide synthase 3 knock-out mice and is elevated in murine and human cirrhosis. Liver Int 24: 345-353.

150. Biecker E, Sägesser H, Reichen J (2004) Cannabinoid receptor 1, nitric oxide synthase 1 and adrenomedullin receptor mRNA levels are increased in the livers of portal hypertensive, nitric oxide synthase 3 deficient mice. Eur J Clin Invest 34 : 283-289.

151. Biecker E, De Gottardi A, Neef M, Unternährer M, Schneider V, Ledermann M, Sägesser H, Shaw SG, Reichen J (2005). Long-term treatment of bile duct ligated rats with sirolimus significantly attenuates liver fibrosis: Analysis of the underlying mechanisms. J Pharm Exp Ther 313: 952-961.

152. Koshy A, De Gottardi A, Ledermann M, Sägesser H, Shaw SG, Zimmermann A, Reichen J (2005). Hyperdynamic circulation in ecNOS knockout mice: ecNOS is not essential for establishement and maintenance of portal hypertension in bile duct ligation. Liver Int 25: 1044-1052

153. Inderbitzin D, Muggli B, Ringger A, Beldi G, Gass M, Gloor B, Uehlinger D, Regli B, Reichen J, Candinas D (2005). Molecular absorbent recirculating system for the treatment of acute liver failure in surgical patients. J Gastrointest Surg. 9:1155-61; discussion 1161-2.

154. Neef M, Ledermann M, Sägesser H, Schneider V, Widmer N, Decosterd LA, Rochat B, Reichen J (2006). Oral imatinib treatment reduces early fibrogenesis but does not prevent progression in the long term. J Hepatol 44: 167-175.

155. Müller NJ, Furrer HJ, Kaiser L, Hirschel B, Cavassini M, Fellay J, Chave JP, Wüthrich RP, Weber M, Müllhaupt B, Candinas C, Reichen J, Giostra E, Mentha G, Halkic N, Hirsch HH, Weber R and the Swiss HIV cohort study. (2006). HIV and solid organ transplantation: The Swiss experience. Swiss Med Wkly 136: 194-196.

156. Shaw SG, Boden JP, Biecker E, Reichen J, Rothen B (2006). Endothelin antagonism prevents diabetic retinopathy in NOD mice: A potential role of the angiogenic factor adrenomedullin. Exp Biol Med 231: 1101-1105.

157. Neef M, Ledermann M, Sägesser H, Schneider V, Reichen J (2006). Long-term low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in bile duct-ligated rats with advanced liver fibrosis. J Hepatol 45: 786-796. Corrigendum (2007) J Hepatol 47: 310.

158. De Gottardi A, Biecker E, Koshy A, Shaw S, Bohler D, Sägesser H, Reichen J (2006). Sensitivity to endothelin-1 is decreased in endothelial constitutive nitric oxide knockout mice. BMC Comp Hepatology http://www.comparative-hepatology.com/content/5/1/9

159. Russmann S, Dowlatshahi EA, Printzen G, Habicht S, Reichen J, Zimmermann H (2007). Prevalence and associated factors of viral hepatitis and transferrin elevations in 5036 patients admitted to the emergency room of a Swiss university hospital: cross-sectional study. BMC Gastroenterology 7: 5.

160. Schoepfer AM, Engel A, Fattinger K, Marbet UA, Criblez D, Reichen J, Zimmermann A, Oneta C (2007). Herbal does not mean innocuous: Ten cases of severe hepatotoxicity associated with dietary supplements from HerbalifeÒ products. J Hepatol 47: 521-526.

161. Schweiger A, Ammann, RW, Candinas D, Clavien PA, Eckert J, Gottstein B, Halkic N, Müllhaupt B, Prinz BM, Reichen J, Tarrr PE, Torgerson PR, Deplazes P (2007). Human alveolar echinococcosis after fox population increase, Switzerland. Emerging Inf Dis 13: 878-882.

162. Veldt BJ, Heathcote EJ, Wedemeier H, Reichen J, Hofmann WP, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL (2007). Sustained virological response leads to an improved clinical outcome for patients with hepatitis C and advanced fibrosis. Ann Int Med 147: 677-684.

163. Knapp AC, Todesco L, Beier K, Terracciano L, Sägesser H, Reichen J, Krähenbühl S (2008). Toxicity of valproic acid in an animal model with impaired b-oxidation associated with carnitine deficiency. J Pharm exp Ther 324:568-575.

164. Bruegger L, Studer S, Schmid S, Pestel G, Reichen J, Seiler C, Candinas D, Inderbitzin D. (2008). Indocyanine green plasma disappearance rate during the anhepatic phase of orthotopic liver transplantation. J Gastrointest Surg, 12: 67-72.

165. Veldt BJ, Chen WD, Heathcote EJ, Wedemeyer H, Reichen J, Hofmann SP, de Knegt RJ, Zeuzem S, Manns MP, Hansen BE, Schalm SW, Janssen HL (2008). Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology, in press.

.

Publications resulting from participation in Multicenter Trials

1. Poynard T, Marcellin P, Lee SS et al. (1998). Randomised trial of interferon a2b plus ribavirin for 48 weeks or for 24 weeks versus interferon a2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet 352: 1456-1472.

2. Trépo C, Jezek P, Atkinson G, Boon R, Young C (2000). Famciclovir in chronic hepatitis B: Results of a dose finding study. J. Hepatol. 32: 1011-1018.

3. Fried MW, Shiffman ML, Reddy KR et al. (2002). Peginterferon Alpha-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982.

4. Marcellin P, Lau GK, Bonino F et al. 2004). Peginterferon Alfa-2a Alone, Lamivudine Alone, and the Two in Combination in Patients with HBeAg-Negative Chronic Hepatitis B. N Engl J Med 351: 1206-127.

Case reports and CPC's

1. Reichen J, Schaefer JW (1982). Chylous ascites after an H-graft inter­position mesocaval shunt. Gut 23: 633-635.

2. Wolfel GH, Campbell DN, Penn I, Reichen J, Warren GH (1983). Inflam­matory polyposis in ileal blind loop. Gastroenterology 84: 1020-1024.

3. Berry W, Warren GH, Reichen J (1984). Nitrofurantoin-induced cholestatic hepatitis in a young male transmitted by cow's milk. West J Med 140: 278-280.

4. Lusk LB, Reichen J, Levine JS (1984). Aphthous ulcerations in diversion colitis: Clinical implications. Gastroenterology 87: 1171-1173.

5. Horber FF, Lerut JP, Reichen J, Zimmermann A, Jäger P and Malinverni R (1992). Visceral leishmaniasis after orthotopic liver transplantation: Impact of persistent splenomegaly. Transplant Int, 6: 55-57.

6. Helbling B and Reichen J (1994). Reaktivierung einer Hepatitis B nach Absetzen von Chloroquin. Schweiz. Med. Wschr. 124:759-762.

7. Bianchi L and Reichen J (1994). Clinicopathology conferences: A 20 year old woman with portal hypertension and a cholestatic syndrome. Hepatology 20: 515-522.

8. Schweizer WP, Nudelmann LI, Baer HU, Steiger U, Reichen J, Triller KJ, Blumgart LH (1995). Intrabiliary rupture of an hydatid cyst of the liver: Combined surgical and interventional radiologic approach to treatment. Current Practice Surg 7: 51-54.

9. Fattinger K, Braunschweig S, Reichen J, Meier-Abt PJ, Krähenbühl S (1997). Leberschädigung unter Tuberkulotstatika-Behandlung. Praxis 86: 626-629.

10. Russmann S, Zimmermann A, Krähenbühl S, Kern B, Reichen J (2001). Veno-occlusive disease, nodular regenerative hyperplasia and hepatocellular carcinoma after azathioprine treatment in a patient with ulcerative colitis. Eur J Gastroenterol Hepatol 13: 287-290.

11. Pfammatter R, Quattropani C, Reichen J, Göke B, Wagner AC (2001). Treatment of hepatic hydrothorax and reduction of chest tube output with octreotide. Eur. J. Gastroenterol Hepatol 13: 977-980.

12. Russmann S, Iselin HU, Meier D, Zimmermann A, Simon HU, Caduff P, Reichen J (2003). Acute hepatitis associated with montelukast. J Hepatol 38: 694-695.

13. Biecker E, Stieger M, Zimmermann A, Reichen J (2003). Autoimmune hepatitis, cryoglobulinemia and untreated celiac disease: A case report. Eur J Gastroenterol Hepatol 15: 423-427.

14. Bihl F, Emmenegger U, Reichen J, Neftel KA, Zimmermann A, Cerny A (2006). Macrophage activating syndrome is associated with lobular hepatitis and severe bile duct injury and cholestasis. J Hepatol 44: 1208-1212.

15. Barth F, Gerber PJ, Reichen J, Dufour JF, Nicod L (2006). Efficiency and safety of bosentan in child C cirrhosis with portopulmonary hypertension and renal insufficiency. Eur J Gastroenterol Hepatol. 18:1117-9.

Review Articles

1. Reichen J, Paumgartner G (1975). Kinetics of hepatic uptake of free and conjugated bile acids by the perfused rat liver. In "Advances in Bile Acid Research", S Matern, J Hackenschmidt, P Back and W Gerok, eds. FK Schattauer Verlag, Stuttgart and New York, pp 223-227.

2. Paumgartner G, Reichen J (1975). The hepatic uptake of bilirubin and taurocholate. In "Chemistry and Physiology of Bile Pigments", PD Berk and NI Berlin, eds. Fogarty International Center Proceedings No. 35. DHEW Publication No. 77-1100. US Government Printing Office, Washington DC, pp 285-291.

3. Paumgartner G, Reichen J, von Bergmann K, Preisig R (1975). Elaboration of hepatocytic bile. Ann N Y Acad Med 51: 455-471.

4. Paumgartner G, Reichen J (1976). Kinetics of hepatic uptake and excretion of organic anions. In "The Biliary System. Fundamental and Pathological Mechanisms." W Taylor, ed. Plenum Press, New York and London, pp 287-296.

5. Paumgartner G, Reichen J (1976). Multiplicity of hepatic uptake mechanisms for organic anions. In "Diseases of the Liver and Biliary Tract", CM Leevy, ed. S Karger Verlag, Basel, pp 65-69.

6. Reichen J, Paumgartner G (1976). Hepatic uptake of taurocholate. In "The Liver. Quantitative Aspects of Structure and Function." R Preisig, J Bircher and G Paumgartner, eds. Editio Cantor, Aulendorf pp 142-149.

7. Reichen J., Paumgartner G (1977). Influence of chemical structure on hepatocellular uptake of bile acids. In "Bile Acid Metabolism in Health and Disease." G. Paumgartner and A Stiehl, eds. MTP Press Ltd, Lancaster, pp 113-123.

8. Jones EA, Steer CJ, Vierling JM and Reichen J (1979). Cell surface receptors in the liver. In "Progress in Liver Disease", volume 6, H Popper and F Schaffner, eds. Grune and Stratton, New York, pp 43-80.

9. Reichen J, Paumgartner G (1980). Excretory function of the liver. Int. Rev. Physiol 21: 103-150.

10. Simon FR, Reichen J (1980). Bile secretory failure: Recent concepts of the pathogenesis of intrahepatic cholestasis. In "Progress in Liver Disease", volume 7, H Popper and F Schaffner, eds. Grune and Stratton, New York, pp 195-206.

11. Reichen J, Simon FR (1982). Cholestasis. In "The Liver. Biology and Pathobiology". IM Arias, H Popper, D Schacter and DA Shafritz, eds. Raven Press, New York, pp 785-800.

12. Reichen J (1983). Familial unconjugated hyperbilirubinemia syndromes. Sem Liver Dis 3: 24-35.

13. Berry W, Reichen J (1983). Bile acid metabolism. Sem Liver Dis 3: 330-350.

14. Reichen J, Simon FR (1984). Mechanisms of Cholestasis. Internat Rev exp Pathol 26: 231-274.

15. Reichen J (1985). Messung der Leberdurchblutung. Methoden, Pathophysiologie und klinische Anwendung. Z Gastroent 20: 128-129.

16. Miotti T, Reichen J (1985). Pharmakologische Therapie der portalen Hypertonie. Schweiz med Wschr 115: 1468-1475.

17. Ohara N, Reichen J (1986). Pharmacological therapy of portal hypertension. Dig Dis 4: 208-219.

18. Preisig R, Reichen J (1987). Cirrhosis. In "Current Hepatology", Year Book Medical Publishers, Chicago, Vol. 7, pp 103-121.

19. Reichen J (1987). Behandlung der Komplikationen der portalen Hypertonie. Ther Umschau 44: 481-488.

20. Reichen J, Lebrec D (1987). The effect of drugs on the portal circula­tion. J Hepatol 5: 235-240.

21. Reichen J, Landmann L, Bradley S.E. (1987). The paracellular pathway: Its role in bile formation. Proceedings of the Calgary Satellite Symposium "Gastrointestinal and hepatic secretion: Mechanisms and control". J.S. Davidson and E.A. Shaffer, eds., University of Calgary Press, Calgary Alberta, Canada.

22. Reichen J (1987). Prescription of drugs in patients with chronic liver disease. Inpharzam Med Forum 11: 24-31.

23. Reichen J, Simon FR (1988). Cholestasis. In "The liver. Biology and Pathobiology", I.M. Arias, W.B. Jakoby, H. Popper, D. Schacter and D. Shafritz, eds., 2nd edition, Raven Press, New York, pp 1105-1124.

24. Zysset T, Reichen J (1988). Anticholestatic agents: Experimental and clinical aspects. In "Liver drugs: From experimental pharmacology to therapeutic application". B Testa and D Perrissoud, eds. CRC Press, pp 113-143.

25. Reichen J and Preisig R (1988). Cirrhosis. In "Current Hepatology". Year book medical publishers, Chicago, Vol. 8, pp. 103-126.

26. Reichen J (1988). Etiology and pathophysiology of portal hypertension. Z Gastroenterol, 26: 3-7.

27. Reichen J (1989). Hepatic spaces and transport. In "Hepatic Transport of Organic substances". E. Petzinger, R.K.H. Kinne and H. Sies, editors. Springer Verlag, Berlin, pp 45-57.

28. Reichen J and Preisig R (1989). Cirrhosis in "Current Hepatology". Year book Medical Publishers, Chicago, Vol. 9, pp 159-186.

29. Reichen J (1988). Pathophysiology der Cholostase. Z Gastroenterol 24: 121-122.

30. Reichen J and Preisig R (1990). Cirrhosis and portal hypertension. In "Current Hepatology". Year book Medical Publishers, Chicago, Vol. 10, pp 141-176.

31. Reichen J (1989). Determinants of liver function in cirrhosis. In "Recent advances in the pathophysiology and therapy of portal hypertension. Serono Symposia Review No. 22, J. Bosch and J. Rodes, editors, SEDA S.R.L. Rome, pp 59 - 75.

32. Reichen J (1990). Pathophysiology of cholestasis. In "Strategies for the treatment of hepatobiliary diseases", G. Paumgartner, A. Stiehl, L. Barbara and E. Roda, editors. Kluwer Academic Publishers, Dordrecht. pp 3-12.

33. Reichen J (1990). Ist eine pharmakologische Behandlung der Leberzirrhose möglich? Schweiz Med Wschr, 120: 557-559.

34. Reichen J (1990). Pharmacological considerations on pathogenesis and treatment of portal hypertension. Hepatology, 11: 1066-1078.

35. Reichen J, Cotting J; Steiger U (1990). Pharmacotherapy of hepatic hydatid disease. In "Infectious diseases of the liver", L. Bianchi, W. Gerok, K.P. Maier and F. Deinhardt, editors, Kluwer Academic Publishers, Dordrecht, pp 235 - 245.

36. Ricci GL, Reichen J and Neuberger J (1990). Primary biliary cirrhosis: Definition and therapeutic trends. Int J Gastroenterol, 3: 127-131.

37. Reichen J, Lavanchy D, Frei P (1990). Seroconversion induced by alfa-2b (INTRON A) ameliorates quantitative liver function in patients with chronic hepatitis B. J Hepatol 11: S172.

38. Reichen J, Paumgartner G, Cotting J and Lentze MJ (1990). Effect of long-term ursodeoxycholate on liver function, nutritional state, and serum bile acids in cystic fibrosis with long-standing cholestasis. In "Bile acids as therapeutic agents. From basic science to clinical practice", G. Paumgartner, A. Stiehl and W. Gerok, editors, Kluwer Academic Publishers, Dordrecht, Boston and London, pp 335-343.

39. Preisig R , Reichen J (1991). Cirrhosis. In "Current Hepatology", G. Gitnick ed, Year Book Medical Publisher, Chicago. Vol. 11 pp 159-197.

40. Reichen J (1991). Liver function in cholestatic liver disease: Implications for treatment. Hepatology Rapid Lit Rev 21: 7-14.

41. Reichen J (1991). Use of the perfused liver in studies of bile secretion. In "Research in perfused liver". F. Ballet and R.G. Thurman, editors. INSERM/John Libby Paris and London, pp 149-163.

42. Reichen J (1992). The treatment of cholelithiasis and cholestasis. In Therapy in Liver Disease. V. Arroyo and J. Rodes, editors. Ediciones Doyma SA, Barcelona, pp 41-44.

43. Reichen J (1992). Physiology of bile formation and of the motility of the biliary tree. In "Oxford Textbook of Clinical Hepatology", N. McIntyre, J.P. Benhamou, J Bircher, M Rizzetto and J. Rodes, editors. Oxford University Press, Oxford 1991, pp 87-94.

44. Preisig R , Reichen J (1992). Cirrhosis. In "Current Hepatology", G. Gitnick ed, Year Book Medical Publisher, Chicago. Vol. 12 pp 187-225.

45. Reichen J (1992). Medikamentöse Behandlung cholestatischer Lebererkrankungen. Ther Umschau 49: 315-325.

46. Reichen J, Roos FJ and Zimmermann H (1992). Functional considerations in the assessment of therapy of chronic cholestatic diseases. In "Paediatric cholestasis. Novel approaches to treatment", M.J. Lentze

and J. Reichen, editors, Kluwer Academic Publishers, Dordrecht 1992, pp 119-126.

47. Cotting J, Dufour JF, Lentze MJ, Paumgartner G, Reichen J (1992). Ursodeoxycholate in the treatment of cholestasis in cystic fibrosis - a 2-year experience and review of the literature. In "Paediatric cholestasis. Novel approaches to treatment", M.J. Lentze and J. Reichen, editors, Kluwer Academic Publishers, Dordrecht 1992, pp 345-353.

48. Krähenbühl S, Reichen J (1992). Adaptation of mitochondrial metabolism in liver cirrhosis. Different strategies to maintain a vital function. Scand J Gastroenterol Suppl 27:90-96.

49. Reichen J (1993). Assessment of liver microcirculation with the multiple indicator dilution technique. Prog Appl Microcirc 19: 40-51.

50. Reichen J (1993). Mechanisms of cholestasis. In "Hepatic transport and bile secretion", N Tavoloni and PD Berk, editors, Raven Press, New York, pp 665-672.

51. Strohmeyer G, Müller R, Baumgarten R, Ferenci P, Hess G, Hopf U, Reichen J, Roggendorf M (1993). Therapie der chronischen Virushepatitis mit alpha-Interferon. Dt Aerztebl 90:867-870.

52. Preisig R, Reichen J (1993). Cirrhosis. In "Current Hepatology", G. Gitnick ed, Year Book Medical Publisher, Chicago. Vol. 13 pp 179-196.

53. Reichen J (1993). Pharmacologic treatment of cholestasis. Sem Liver Dis 13:302-315.

54. Reichen J (1993). Hyperdynamic circulation in chronic liver disease: Significance and pathogenesis. In "Extrahepatic manifestations in liver disease. R. Schmid, L. Bianchi, W. Gerok and K.P. Maier, editors. Kluwer Academic Publishers, Dordrecht, pp 77-92.

55. Reichen J, Krähenbühl S, Wirth HP and Maier KP (1993). Liver function in cholestatic liver disease: A critical appraisal. In "Bile acids and the hepatobiliary system". G. Paumgartner, A. Stiehl and W. Gerok, editors. Kluwer Academic Publishers, Dordrecht, pp 258-270.

56. Reichen J. (1993). Utilisation du foie perfusé dans les études sur la sécrétion biliaire. In "Recherches en foie isolé perfusé". F. Ballet and R.G. Thurman, editors. INSERM/John Libbey, Paris. pp 171-187.

57. Reichen J, Krähenbühl S, Zimmermann H (1994). Impact of cholestasis on hepatic function: Retention of cholephiles and their potential targets. In "Cholestasis", P. Gentilini, IM Arias, N. McIntyre and J. Rodes, editors. Excerpta Medica, Amsterdam, pp 167 - 176.

58. Zimmermann H, Reichen J (1994). Assessment of liver function in the surgical patient. In "Surgery of the Liver and Biliary tract", LH Blumgart, editor. Churchill Livingstone, Edinburgh, pp 41-64

59. Reichen J (1995). Prescribing in liver disease. In “Treatments in Hepatology”, V. Arroyo, J. Bosch and J. Rodes, editors. Masson SA, Barcelona, pp 399-406.

60. Reichen J (1995). Pharmacology of portal and splanchnic perfusion with particular reference to microvascular exchange and heptic function. In “Portal hypertension”, A. Holstege, E.G. Hahn and J. Schölmerich, editors. Kluwer Academic Publishers, pp 133-146.

61. Reichen J (1995). Assessment of hepatic function with xenobiotics. Sem. Liver Dis. 15: 189-201.

62. Gottstein B, Reichen J (1995), Echinococcosis/hydatidosis. In “Manson’s Tropical Diseases”, G.C. Cook, editor. 20th edition. WB Saunders Company Ltd, London. pp 1509-1516.

63. Reichen J, Zimmermann H (1996). Liver function tests for follow-up and assessment of prognosis of bilirary diseases. In „Bile acids - cholestasis - gallstones“, H. Fromm and U. Leuschner, editors, Kluwer Academic Publishers, Dordrecht, pp 349-359.

64. Reichen J (1996). Analysis of experimental data on the concept of interactions between bile salts and immunological effector reactions. In „Bile Acids and Immunology“, P.A. Bern and U. Leuschner, editors. Kluwer Academic Publishers, Dordrecht, pp. 281-289.

65. Reichen J (1996). Diagnostic approach to cholestasis. J. Hepatol. 25 (Suppl. 1): 17-22.

66. Gangl A, Lammer J, Pidlich J, Reichen J, Rössle M, Steiniger R, Vogel W (1996). Offene und kontroverse Fragen zur portalen Hypertonie. Chir. Gastroenterol. 12: 350-357.

67. Reichen J (1997). Prescribing in liver disease. J. Hepatol. 26 (Suppl. 1): 36-40.

68. Seiler CA, Renner EL, Schilling M, Reichen J, Büchler MW (1997). Die Lebertransplantation am Inselspital: Resultate der letzten 5 Jahre. Schweiz. Med. Wochenschr. 127 (Suppl. 89): 31S – 35 S.

69. Zimmermann H, Reichen J (1998). Hepatectomy: Preoperative analysis of hepatic function and postoperative liver failure. Dig. Surg. 15:1-11.

70. Krähenbühl S, Reichen J (1998). Prescribing in patients with liver cirrhosis. Medicine 26: 23-26.

71. Reichen J (1999). The role of sinusoidal endothelium in liver function. News Physiol. Sci. 14: 117-120.

72. Reichen J (1999). Portal hypertension: Cytokines and endothelin. Hepatogastroenterology 46: 1434-1436.

73. Krähenbühl S, Reichen J (1999). Drug hepatotoxicity in 'Liver disease: Diagnosis and management.' Bacon BR and Di Bisceglie AM. Editors. Churchill Livingstone New York. pp 294-308.

74. Reichen J (1999). Experimental portal hypertension. A review of models and techniques. Rom. J. Gastroenterol. 8: 265-267.

75. Reichen J, Frey B, Frey FJ (2000). Effect of bile duct ligation and bile salts on the activity of 11b-hydroxysteroid dehydrogenase: Another explanation for mineralocorticoid excess in biliary cirrhosis in the rat. In "Bile acids in hepatobiliary diseases". TC Northfield, H.. Ahmed and R. Jazwari, editors. Kluwer Academic Publishers, Dordrecht, pp. 6-12.

76. Vogt B, Reichen J (2000). Rationale Diuretikatherapie bei Leberzirrhose. Ther. Umschau 57: 355-360.

77. Zimmermann J, Reichen J (2000). Assessment of liver function in the surgical patient. In "Surgery of the Liver and Biliary Tract", Blumgart LH and Fong Y, eds. W.B. Saunders, London, pp 35 - 64.

78. Reichen J, Vogt B, Frey B, Frey FJ (2001). Down-regulation and inhibition of 11b-hydroxysteroid dehydrogenase: Another explanation for sodium retention and ascites formation in bile duct ligated rats. In 'Hepatology 2000'; Gerbes AL, Beuers U, Jüngst D, Pape GR and Sackmann M, eds. Kluwer Academic Publishers Dordrecht, pp 13-19.

79. Zbinden AM, Reichen J (2001). How to read and interpret medical literature. In 'Conducting research in anesthesia and intensive care medicine. AM Zbinden and RD Thomson, editors. Butterworth-Heinemann, Oxford, pp 21-59.

80. Reichen J, Krähenbühl S (2001). Use of drugs in liver disease. In "Clinical Pharmacology", C. Sirtori, editor in chief. McGraw Hill London, chapter 36, pp 379-383.

81. Reichen J (2001). What is the significance of cryoglobulinemia in patients with hepatitis C and how is it treated? Advances in Hepatitis C, 1: 15-16.

82. Reichen J (2002). Classification of liver cirrhosis. In 'Chronic pancreatitis', MW Büchler, H Friess, W Uhl and P Malfertheiner, editors. Blackwell Wissenschaftsverlag Berlin, pp 299-303.

83. Hunziker IP, Zurbriggen R, Glueck R, Engler OB, Reichen J, Wai WJ, Pichler WJ, Cerny A (2001). Perspectives: Towards a peptide-based vaccine against hepatitis C virus. Mol Immunol 38: 475-484.

84. Gottstein B, Reichen J (2002). Hydatid lung disease (echinococcosis/hydatidosis). Clin Chest Med 23: 397-408.

85. Gallati S, Reichen J (2002). Pathophysiologie des Eisenstoffwechsels und Genetik der Hämochromatose. Swiss Med Forum 41: 966-970.

86. Reichen J, Zimmermann A, Gallatti S (2002). Klinik, Diagnose und Behandlung der hereditären Hämochromatose. Swiss Med Forum 42: 996-1001.

87. Krähenbühl S, Reichen J (2002). Pharmacokinetics and pharmacodynamics in cirrhosis. Medicine 30: 24-27.

88. Gottstein B, Reichen J (2003). Echinococcosis /hydatidosis. In ‚Manson’s Tropical Diseases’, GC Cook and A Zumla, editors. W.B. Saunders, 21st edition. Chapter 84, pp 1561-1582.

89. Reichen J (2003). Gallensteine: Natürliche Geschichte und konservative Behandlung. Therapeutische Umschau 60: 109-112.

90. Burckhardt B, Reichen J (2003). Therapie der viralen Hepatitiden. Therapeutische Umschau 60: 651-656.

91. Reichen J (2004). Evaluation of portal hemodynamics using indicator dilution and noninvasive techniques. In ‘Clinical Gastroenterology: Portal hypertension’. AJ Sanyal and VS Shah, editors. Humana Press Totowa NJ. pp 145-154.

92. Russmann S, Reichen J (2005). Drug prescription in liver disease. In ‘Clinical Gastroenterology and Hepatology’, Weinstein WM, Hawkey CJ, Bosch J editors. Elsevier Mosby, pp 1015-1019.

93. Gschossmann J, Essig M, Reichen J, Scheurer U, Gerken G (2006). The hepatopulmonary syndrome – where do we stand in 2006? Z Gastroenterol 44: 249-256.

94. Seiler CA, Dufour JF, Reichen J, Candinas D (2006). Lebertransplantation 2006: Was sollte der niedergelassene Arzt wissen? Schweiz Med Forum 6: 312-318.

95. Reichen J (2006). Leberzirrhose und ihre Komplikationen. In ‚Hepatologie für die Praxis’, G.R. Pape und B. Göke, Editors. Urban und Fischer, München – Jena pp 145-160.

96. Reichen J, Lebrec D (2007). The future treatment of portal hypertension. Best Practice and Research Clinical Gastroenterology 21:191-202.

Editorials

1. Reichen J, Renner E.L. (1991). The role of bile salt uptake in canalicular bile formation. Transport systems and acinar heterogeneity. J Hepatol 14:140-143.

2. Reichen J (1993). The MEGX test in hepatology: The long-sought ultimate quantitative liver function test? J Hepatol, 19:4-7.

3. Reichen J (1993). Splenektomie bei unerkannter portaler Hypertonie: EIn riskantes Unterfangen. Schweiz. Med. Wschr. 123: 2305-2308.

4. Büchler MW, Reichen J (1998). Chirurgische und konservative Behandlung von Lebererkrankungen. Therapeutische Umschau 55: 69-70.

5. Reichen J (1995). Commentary to 'Trimethoprime-sulfamethoxazole reduced bacterial peritonitis occurrence in cirrhosis' by Singh et al. (Ann. Int. Med. 122: 595-598). ACP Journal Club 123:42.

6. Reichen J (2000). Commentary to 'Endoscopic ligation was better than propranolol for prevention of bleeding from esophageal varices. ACP Journal Club 132: 21.

7. Reichen J (2000). Commentary to 'Long-term ursodeoxycholic acid does not prevent mortality or morbidity in primary biliary cirrhosis. ACP Journal Club 132: 68.

8. Reichen J (2002). Commentary to ‘Interferona plus Ribavirin improves the virologic response in chronic hepatitis C. ACP Journal Club 137:17.

9. Reichen J (2003). Commentary to ‘Flumazenil is effective in hepatic encephalopathy with cirrhosis. ACP Journal Club 138: 15.

10. Reichen J (2006). Commentary to ‘The natural history of nonalcoholic liver disase: A population based cohort study. ACP Journal Club 144:22.

11. Reichen J (2006). Quantitative liver tests in living liver donors and their recipients. Liver Transpl 12: 514-515.

12. Reichen J (2006). Entecavir was more effective than lamivudine in HbeAg-positive chronic hepatitis B. ACP Journal Club 145 http://www.acpjc.org/Content/145/1/issue/ACPJC-2006-145-1-018.htm

13. Reichen J (2008). Ursodeoxycholic acid does not reduce risk for mortality or liver transplantation in primary biliary cirrhosis. ACP J Club 148: 17.

Editorships

1. Reichen J and Lentze M (1992). Pediatric cholestasis. Novel approaches to treatment. Kluwer Academic Publishers, Dordrecht.

2. J. Reichen and R.E. Poupon (1996). Surrogate markers to assess efficacy of treatment in chronic liver disease. Kluwer Academic Publishers, Dordrecht.

3. Büchler MW und Reichen J (1998). Lebererkrankungen. Therapeutische Umschau 55: 69-149.

4. J. Schölmerich (2003). Medizinische Therapie in Klinik und Praxis. S. Burdach, V. Diehl, H. Drexler, W. Hildemann, WH Hörl, H Klein, M. Landthaler, K Lenz, K. Mann, J Mössner, U Müller-Ladner, J. Reichen, W Schmiegl, JO Schröder, W Seeger, W Stremmel, N Suttorp LS Weilemann, Mitherausgeber. Springer Verlag Berlin Heidelberg.

Letters

1. Reichen J (1990). Effect of secretin on bile formation. Reply to a letter by A.E. Dumont. Gastroenterology 98: 1393-1394.

2. Aebli N and Reichen J (1990). Betrifft: Prognostische Wertigkeit der seriellen Bestimmung der Galaktoseeliminationskapazität bei chronisch aktiver Hepatitis. Schweiz Med Wschr 121: 1628.

3. Reichen J (1992). Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis: A comparison with the Mayo model. Reply to a selected summary by J. Gross. Gastroenterology 103:1361.

4. Widler P, Fisch HU, Schläpfer T and Schoch P (1994). The involvement of benzodiazepine receptor ligands in hepatic encephalopathy. Reply to a letter by A.S. Basile and E.A. Jones. Hepatology 20: 543.

5. Widler P, Fisch HU, Schläpfer T and Schoch P (1994). The involvement of benzodiazepine receptor ligands in hepatic encephalopathy. Reply to a letter by R. Gacad, K. Kaminsky-Russ and KD Mullen. Hepatology 20: 545-546.

6. Rauch A, Egger M, Reichen J, Furrer HJ and the Swiss HIV cohort study (2005). Chronic hepatitis C in HIV infected patients: Low eligibility and applicability of therapy with pegylated interferon alfa and Ribavirin. J AIDS 38: 238-240.

Abstracts

1. Reichen J, Paumgartner G (1973). Michaelis-Menten kinetics and diffusion describing hepatic uptake of taurocholate. Digestion 9: 545.

2. Reichen J, Paumgartner G (1974). Dependence of hepatic uptake on chemical structure and conjugation of bile salts. Digestion 10: 313.

3. Paumgartner G, Reichen J, Preisig R (1974). Evaluation of 14-C-taurocholate for estimation of hepatic blood flow in man. Digestion 10: 372.

4. Reichen J, Paumgartner G (1979). Kinetics of the uptake of organic anions in the perfused rat liver. Eur J Clin Invest 4: 325.

5. Reichen J, Paumgartner G (1974). Kinetics of bile salt transport by the perfused rat liver. Experientia 30: 682.

6. Paumgartner G, Reichen J (1974). Different pathways for hepatic uptake of taurocholate and indocyanine green. Gastroenterology 67: 814.

7. Paumgartner G, Reichen J (1974). Influence of chemical structure on hepatic uptake of bile salts. Gastroenterology 67: 819.

8. Reichen J, Paumgartner G (1975). Sodium dependence of the hepatocellular uptake of taurocholate. Evidence for carrier-mediated transport. Digestion 11: 273.

9. Paumgartner G, Reichen J (1975). Separate carrier-mediated transport systems for the hepatocellular uptake of bilirubin and bile acids. Digestion 11: 259.

10. Reichen J, Paumgartner G (1975). Sodium dependent membrane transport responsible for hepatocellular uptake of taurocholate. Gastroenterology 70: 855.

11. Reichen J, Messerli J, Paumgartner G (1976). Decreased Na,K-ATPase activity in canalicular membranes of cholestatic rat liver. Experientia 32: 760.

12. Reichen J, Paumgartner G (1976). Decreased Na,K-ATPase activity in taurolithocholate-induced cholestasis in the rat. Digestion 12: 541.

13. Reichen J, Paumgartner G (1976). Definition of Na,K-ATPase-dependent bile formation in the rat. Digestion 12: 528.

14. Reichen J, Karlaganis G, Paumgartner G (1976). Mechanism of hydrocor­disone-induced choleresis in rat. Digestion 12: 541.

15. Reichen J, Paumgartner G (1976). Definition of Na,K-ATPase-dependent bile flow in rat. Gastroenterology 71: 925.

16. Reichen J, Blitzer BL, Berk PD (1977). The binding of organic anionic dyes to hepatocellular plasma membranes. Clin Res 25: 268A.

17. Reichen J, Berk PD (1978). Isolation of an organic anionic dye binding protein from rat liver plasma membranes. Gastroenterology 73: 1242.

18. Reichen J, Berk PD (1978). Differential effects of taurolithocholate and taurocholate on protein excretion into bile. Clin Res 26: 499A.

19. Reichen J, Berman MD (1978). The role of microtubules and microfilaments in bile salt uptake by isolated rat hepatocytes. Gastroenterology 74: 1167.

20. Berman MD, Reichen J (1979). Abnormal bile salt uptake by isolated hepatocytes from rats with hepatic fibrosis. Gastroenterology 75: 955.

21. Finck MH, Brown WR, Vierling JM, Reichen J (1982). Differential hepatic handling of IgA and asialoorosomucoid by the perfused rat liver. Clin Res 30: 282A.

22. Reichen J, Le M (1982). Quantitation of para- and transcellular water flow in the formation of canalicular bile by the perfused rat liver. Clin Res 30: 288A.

23. Hoilien C, Kirshenbaum G, Reichen J (1982). Effects of fasting on CO production, heme oxygenase and cytochrome P-450 in the rat. Gastro­enterology 82: 1086.

24. Reichen J, Le M (1982). Taurocholate-induced cholestasis is associated with a loss of bile secretory pressure and increased permeability of the biliary tree. Gastroenterology 82: 1158.

25. Reichen J, Hoilien C, Kirshenbaum G (1982). Cimetidine induces heme oxygenase without concurrent degradation of cytochrome P-450. Hepatology 2: 697.

26. Reichen J, Le M (1983). Sinusoidal capillarization is more important than intrahepatic shunting to explain decreased propranolol clearance in liver cirrhosis. Clin Res 31: 33A.

27. Finck MH, Brown WR, Vierling JM, Reichen J (1983). Hepatic uptake and metabolism of asialo-immunoglobulin in the rat. Clin Res 31: 31A.

28. Fritzberg AR, Reichen J (1983). Direct measurement of extraction ef­ficiencies and mean transit times of hepatobiliary agents in the perfused rat liver. J Nucl Med 24: 126P.

29. Kloppel TM, Reichen J, Brown WR (1983). Synthesis and secretion of secretory component into rat bile. Fed Proc 42: 213A.

30. Kloppel TM, Reichen J, Brown WR (1983). Evidence that secretory component in rat bile is a proteolytic product of hepatocyte membrane. Gastroenterology 84: 1379.

31. Finck MH, Kloppel TM, Brown WR, Vierling JM, Reichen J (1983). Hepatic uptake and metabolism of asialoimmunoglobulin A in the rat. Gastroenterology 84: 1152.

32. Reichen J, Le M (1983). Effect of taurocholate on place and rate of entry of sucrose into the bile canaliculus. Gastroenterology 84: 1283.

33. Berry W, Kirshenbaum G, Hoilien C, Reichen J (1983). Taurocholate increases heme catabolism and alters the metabolic fate of antipyrine in the rat. Gastroenterology 84: 1104.

34. Reichen J, Le M (1983). Sinusoidal capillarization is more important than intrahepatic shunting to explain decreased propranolol clearance in liver cirrhotic rats. Gastroenterology 84: 1283.

35. Reichen J, Berr F, Le M (1983). Calcium deprivation increases biliary permeability and leads to failure to translocate bile acids in the perfused rat liver. Hepatology 3: 834.

36. Berry W, Hoilien C, Reichen J (1983). Phalloidin alters hepatic micro­somal enzymes and decreases antipyrine clearance in the rat. Hepatology 3: 834.

37. Berr F, Simon FR, Reichen J (1983). Ethinyl estradiol administration decreases bile salt and Na,K pump function in isolated rat hepatocytes. Hepatology 3: 834.

38. Reichen J, Le M (1984). Differences in bile salt secretion and bile formation between centrizonal and periportal hepatocytes. Clin Res 32: 77A

39. Kloppel TM, Brown WR, Reichen J (1984). Biliary secretion of de novo synthesized hepatic proteins. Clin Res 32: 26A.

40. Kloppel TM, McCracken A, Brown WR, Reichen J (1984). Sorting of newly synthesized hepatic secretory proteins in the perfused rat liver: Direct demonstration of three distinct pathways. Gastroenterology 86: 1326.

41. Reichen J, Le M (1984). Differences in bile salt secretion and bile formation between centrizonal and periportal hepatocytes. Gastroenterology 86: 1336.

42. Kloppel TM, Brown WR, Reichen J (1984). Effects of monensin in the biliary secretion of secretory component in the perfused rat liver. Fed Proc 43: 1846.

43. Hoilien C, Berry W, Reichen J (1984). Decreased uptake of taurocholate and ouabain by cirrhotic rat hepatocytes: Evidence for the sick cell hypothesis. Hepatology 4: 750.

44. Reichen J, Le M (1984). Verapamil favourably alters the microcirculatory changes of cirrhosis in rat liver. Hepatology 4, 1027.

45. Reichen J, Sägesser H, Küpfer A (1985). Impaired bile salt transport in a rat with genetic hydroxylation deficiency. Clin Res 33: 97A.

46. Reichen J, Le M (1985). Taurolithocholate induces cholestasis by altering transcellular but not paracellular biliary permeability. Clin Res 33: 97A.

47. Kloppel T, Reichen J (1985). Effects of monensin on transport of secretory and membrane proteins in the perfused rat liver. Fed Proc 44: 711.

48. Brown W, Reichen J, Kloppel T (1985). Kinetics of secretion of secretory component by the perfused rat liver. Fed Proc 44: 1303.

49. Krähenbühl S, Sägesser H, Küpfer A, Reichen J (1985). Bile salt uptake defect in a hydroxylation deficient rat. Gastroenterology 88, 1671.

50. Reichen J, Sägesser H (1985). Hepatic arterial blood flow is functionally less important than portal veinous flow in cirrhotic rat liver. Gastroenterology 88, 1687.

51. Gross Jr. JB, Zimmermann A, Reichen J (1985). The sick cell vs intact cell hypothesis: Relationship of in vivo breath tests to morphometric measurement of hepatocyte mass in cirrhosis. Hepatology 5, 962.

52. Reichen J, Sägesser H, Ha HR, Hirlinger A (1985). Liver function and extravascular albumin space, a major determinant of drug metabolism, is increased by verapamil in rats with liver cirrhosis in vivo. Hepatology 5, 987.

53. Reichen J, Sägesser H (1985). Role of the hepatic artery in bile formation in the rat. Hepatology 5, 987.

54. Gross JB, Zimmermann A, Reichen J (1985). Serial changes in results of quantitative liver function tests during development of cirrhosis in the rat: Partially useful prognostic patterns. J Hepatol S2, S246.

55. Hirlinger A, Sägesser H, Reichen J (1985). Chronic verapamil administration improves liver function and diffusional exchange in a rat model of liver cirrhosis. J Hepatol S2, S253.

56. Miotti T, Reichen J (1985). Verapamil improves fractional clearance of indocyanine green in patients with liver cirrhosis. J Hepatol S2, S291.

57. Miotti T, Karlaganis G, Reichen J, Bircher J (1985). Quantitation of portal systemic shunting in cirrhotic and non-cirrhotic patients with chronic liver disease. J Hepatol S2, S291.

58. Reichen J, Egger B, Gross JB jr., Zeltner T, Zimmermann A (1986). Morphometric and functional differences between micronodular (MC) and biliary cirrhosis (BC) in the rat. Hepatology 6, 1122.

59. Reichen J, Sägesser H (1986). Bile salts decrease water exchange and increase biliary permeability in the portal venous but not the hepatic arterial bed. Hepatology 6, 1122.

60. Karlaganis G, Kern F, Reichen J (1986). Increased hepatic cholesterol synthesis without adaptation of bile acid synthesis as a risk factor for cholesterol gallstones. A study in pregnant hamster. Hepatology 6, 1122.

61. Reichen J, Egger B, Zimmermann A (1986). Intrahepatic shunts, not intrinsic clearance, determine serum bile acid levels in a rat model of liver cirrhosis. Hepatology 6, 1123.

62. Ohara N, Reichen J (1986). Aminopyrine breath test predicts changes in hepatocyte microsomal function but not hepatocyte mass in bile duct ligated cirrhotic rats. Hepatology 6, 1206.

63. Zysset T, Arts B, Egger B, Zimmermann A, Reichen J (1986). Is the aminopyrine breath test a measure of microsomal function or of diffusional exchange in cirrhotic rat liver? J Hepatol S1, S66.

64. Egger B, Zimmermann A, Reichen J (1986). Determinants of serum bile acid levels (SBA) in a rat model of liver cirrhosis. J Hepatol S1, S62.

65. Reichen J, Sägesser H (1986). Differential effect of bile acids on biliary permeability in the hepatic arterial (HA) and portal venous (PV) bed. J Hepatol S1, S156.

66. Pirovino M., Müller O, Honegger UE, Reichen J, Zysset T, Stäubli M, Studer H (1986). Amiodarone: A model drug to study the interrelation between altered hepatocellular structure and function. J Hepatol S1, S63.

67. Karlaganis G, Kern F, Reichen J (1986). Increased cholesterol synthesis in near-term pregnant hamsters: A cause for the increased risk to develop cholesterol gallstones? J Hepatol S1, S61.

68. Cotting J, Widmer T, Bircher J, Preisig R, Reichen J (1987). Capacité d'élimination du galactose (GEC) dans la cirrhose biliaire primitive: Meilleure valeur prognostique que le taux the bilirubine ? Gastroentérol Clin Biol 11, 2bis, 169A.

69. Cotting J, Sägesser H, Zysset Th, Reichen J (1987). Extraction hépatique du C14-glycocholate et du d-propranolol durant l'obstruction biliaire chez le rat: Evidence pour la regurgitation biliaire lors de la cholostase. Gastroentérol Clin Biol 11, 2bis, 256A.

70. Ohara N, Reichen J (1987). Fasting impairs hepatic galactose elimination capacity (GEC) and galactose breath test (GBT) Kb in rats. Fed Proc, 46: 916.

71. Cotting J, Widmer T, Bircher J, Preisig R, Reichen J (1987). Serial determination of galactose elimination capacity in primary biliary cirrhosis is of better prognostic value than serum bilirubin. J Hepatol 5: S20.

72. Krähenbühl S, Reichen J (1987). Permeabilities to sucrose and ferro­cyanide and maximal biliary pressure are increased in cirrhotic rats. J Hepatol 5: S36.

73. Oehler R, Bradley SE, Zysset T, Reichen J (1987). Effect of free and taurine-conjugated dehydrocholate on canalicular electronegativity and biliary gentamicin excretion. J Hepatol 5: S49.

74. Reichen J, Sägesser H, Stuber R, Zysset T (1987). Effect of norepinephrine on transport function of normal liver. J Hepatol 5: S54.

75. Roos FJ, Zysset T, Talos C, Reichen J (1987). Is increased microsomal membrane rigidity responsible for decreased dextrometorphan demethylation in bile duct ligation-induced cirrhosis in the rat? J Hepatol 5: S57.

76. Cotting J, Kutz K; Laplanche R, Nüesch E, Reichen J (1987). Pharmacokinetics of a new calcium channel blocker, isradipine, in patients with chronic liver disease. J Hepatol 5: S114.

77. Navasa M, Bosch J, Reichen J, Mastai R, Zysset T, Bru C, Silva G, Chesta J, Rodes J (1987). Effects of verapamil on portal hypertension and liver function in cirrhosis. J Hepatol 5: S176.

78. Reichen J, Sägesser H, Stuber R, Zysset T (1987). Resistance of cirrhotic rat liver to the microvascular and functional effects of norepinephrine: Down-regulation of hepatic adrenoceptors ? Hepatology 7: 1032.

79. Stammler L, Landmann L, Bianchi L, Reichen J (1987). Stereological analysis of calcium deprivation-induced cholestasis in the rat: Evidence for altered hepatocellular osmotic regulation. Hepatology 7: 1040.

80. Cotting J, Reichen J (1987). Decrease in maximal bile secretory pressure induced by taurocholate: Further evidence for a role of bile salts in the regulation of biliary permeability. Hepatology 7: 1069.

81. Bradley SE, Zysset T, Reichen J, Preisig R (1987). Concomitants of sulfobromophthalein sodium increase in biliary gentamicin excretion in rats. Hepatology 7: 1070.

82. Cotting J, Widmer T, Bircher J, Preisig R, Reichen J (1987). Accurate prediction of death by serial determination of galactose elimination capacity in primary biliary cirrhosis. Hepatology 7: 1119.

83. Roos FJ, Zysset T, Talos C, Reichen J (1987). Increased microsomal membrane rigidity is responsible for altered drug metabolism in biliary but not micronodular cirrhosis in the rat. Hepatology 7: 1130.

84. Pirovino M, Reichen J (1987). Amiodarone-induced hypercholesterolemia: Lack of feed-back inhibition of hepatic cholesterol synthesis. Hepatology 7: 1137.

85. Krähenbühl S, Knuchel J, Zimmermann A, Reichen J (1988). Ductular epithelium of cirrhotic rat liver is responsive to secretin and permeable to erythritol. Gastroenterology 94: A556.

86. Everson GT, Leff N, Zogg D, Reichen J, Gabow P (1988). Polycystic liver disease: Quantitative assessment of hepatic and cyst function. Gastroenterology 94: A538.

87. Krähenbühl S, Stucki J, Reichen J (1988). Reduced velocity of ATP production and decreased respiratory control in mitochondria isolated from cirrhotic rat liver. Gastroenterology 94: A556.

88. Cap L, Krähenbühl S, Reichen J, Lauterburg BH (1988). Assessment of mitochondrial function in vivo: Validation of a breath test using 14C-keto-isocaproic acid in alcoholic and cirrhotic rats. J Hepatol 7: S17.

89. Cotting J, Sägesser H, Reichen J (1988). Loss of permselectivity of the biliary tree in cholestasis: Differential effects of ethinyl estradiol- and phalloidin-induced cholestasis in the rat. J Hepatol 7: S22.

90. Krähenbühl S, Knuchel J, Zimmermann A, Reichen J (1988). Ductular proliferation, not altered pharmacokinetics of secretin, is responsible for hypercholeresis in cirrhotic rats. J Hepatol 7: S45.

91. Zimmermann H, Reichen J, Höflin F, Sägesser H, Blumgart LH (1988). Relief of bile duct obstruction resolves portal hypertension and improves liver function in rats with secondary biliary cirrhosis. J Hepatol 7: S86.

92. Cotting J, Lentze M and Reichen J (1989). Ursodeoxycholic acid treatment improves liver disease and nutritional state in cystic fibrosis patients with chronic cholestasis. Gastroenterology 96: A586.

93. Gerbes AL; Kollenda MC, Vollmar AM, Reichen J, Vakil N, Scarbrough,RM (1989). Density of glomerular binding sites for atrial natriuretic factor (ANF) is altered in rats with cirrhosis and ascites. Hepatology 10: 588.

94. Zimmermann H, Reichen J, Sägesser H, Zimmermann A, Gehr P (1989). Biliodigestive anastomosis reverses secondary biliary cirrhosis in the rat. Hepatology 10: 626.

95. Krähenbühl S, Gehr P, Stucki J, Reichen J (1989). Mitochondrial and cytosolic function in cirrhotic liver: Divergent behaviour of intermediary metabolism. Hepatology 10: 650.

96. Hirlinger A, Sägesser H and Reichen J (1989). Heavy water decreases bile salt-independent bile flow and increases paracellular permeability in perfused rat liver. J Hepatol 9: S41.

97. Jordi I and Reichen J (1989). Disturbed feed-back inhibition of hepatic cholesterol synthesis in biliary cirrhosis in the rat. J Hepatology 9: S47.

98. Hirlinger A, Sägesser H, Reichen J (1990). Ursodeoxycholic acid­induced biliary bicarbonate secretion is inhibited by heavy water. J Hepatol 11: S30.

99. Oguey D, Marti U, Sägesser H, Reichen J (1990). Is epidermal growth factor receptor involved in the maintenance of hepatocyte mass in cirrhosis) J Hepatol 11: S47.

100. Reichen J, Dueland S, Davis A (1990). Bile acid synthesis is stimulated in chroniv biliary obstruction, Does free cholesterol regulate bile acid synthesis? J Hepatol 11: S52.

101. Zimmermann H, Thenisch B, Reichen J (1990). Failure of ursodeoxycholate to influence liver function or histology in biliary cirrhosis in the rat. J Hepatol 11: S67.

102. Increased flux of bile through the liver stimulates liver growth and alters the electric properties of the sinusoidal-canalicular barrier. J Hepatol 11: S 67.

103. Dufour JF, Talos C, Reichen J (1990). Cholestasis is determinant in increase of lysosomal activity in liver cirrhosis. J Hepatol 11: S20.

104. Aebli N, Reichen J (1990). Serial determinations of galactose elimination capacity yields accurate prognostic information in chronic active hepatitis. J Hepatol 11: S69.

105. Reichen J, Male PJ, Chevilli S, Gonvers JJ, Altorfer J, Bühler H, Lavanchy D, Frei PC (1990). Seroconversion ameliorates liver function in patients with chronic active hepatitis B: Results from a randomized, controlled trial. J Hepatol 11: S108.

106. Steiger U; Cotting J, Terrier F, Reichen J (1990). Albendazole therapy in human hepatic alveolar echinococcosis; Encouraging preliminary results. J Hepatol 11: S114.

107. Marti U, Hirlinger A, Sägesser H, Reichen J (1990). Heavy water impairs early steps in the hepatic handling of epidermal growth factor. J Hepatol 11: S101.

108. Reichen J (1990). Prediction of death in primary biliary cirrhosis: Validation of a model based on serial determination of galactose elimination capacity. Hepatology 12: 434.

109. Reichen J, Krähenbühl S, Gehr P, Stucki J (1990). Disparate compensatory mechanisms in micronodular and biliary cirrhosis. Hepatology 12: 434.

110. Zimmermann H, Sägesser H, Thenisch B and Reichen J (1990). Retention of bile induces portal hypertension but not biliary cirrhosis in the rat. Hepatology 12: 854.

111. Dufour JF, Gehr P, Talos C, Tenisch B, Sägesser H, Reichen J (1991). Increase of plasmatic and hepatic lysosomal activity in cirrhotic rats: Potential relationship with a defect in transcytosis. Gastroenterology 100: A738.

112. Dufour JF, Stoupis C, Lazeyras F, Terrier F, Vock P and Reichen (1991). Abnormalities of fructose metabolism of the liver in human cirrhosis demonstrated by dynamic 31-P spectroscopy. Gastroenterology 100: A738.

113. Elsing C and Reichen J (1991): Different sensitivity of carbonic anhydrase to deuterium oxide in hemolysate and rat liver cytosol. Experientia 47: A19.

114. Dufour JF, Gehr P, Talos C, Tenisch B, Sägesser H and Reichen J (1991). Increase of plasmatic and hepatic lysosomal activity in cirrhotic rats: Potential relationship with a defect in transcytosis. Gastroenterology 100: A738.

115. Dufour JF, Stoupis C, Lazeyras F, Terrier F, Vock P and Reichen J (1991). Abnormalities of fructose metabolism of the liver in human cirrhosis demonstrated by dynamic P-31 spectroscopy. Gastroenterology 100: A738.

116. Elsing C, Renner E, Reichen J (1991). The cholestatic effect of deuterium oxide: Differential isotope effect on carbonic anhydrase and on Na,H, antiporter. J Hepatol 13: S26.

117. Marti U, Mary JL, Reichen J and Schwander J (1991). Induction of insulin-like growth factor binding protein 2 in liver cirrhotic rats. J Hepatol 13: S51.

118. Oguey D, Marti U, Sägesser H and Reichen J (1991). Differential effect of micronodular and biliary cirrhosis on epidermal growth factor receptor binding and expression. J Hepatol 13: S57.

119. Zimmermann H, Blaser H, Reichen J (1992). Age-dependent changes in the development of secondary biliary cirrhosis in the rat. J Hepatol 16: S34.

120. Widler P, Fisch HU, Schoch P, Schläpfer TE, Zimmermann A, Reichen J (1992). Are endogeneous benzodiazepine receptor ligands relevant in the pathogenesis of hepatic encephalopathy? J Hepatol 16: S39.

121. Elsing C, Sägesser H, Reichen J (1992). Role of the ductular epithelium in ursodeoxycholate induced hypercholeresis. J Hepatol 16: S67.

122. Krähenbühl S, Talos C, Reichen J (1992). Bile acid toxicity in isolated rat liver mitochondria: Nonspecific membrane effects of lipophilic bile acids and specific impairment of the electron transport chain by chenodeoxycholate. J Hep7atol 16: S68.

123. Fischer G, Sägesser H, Talos C, Reichen J (1992). S-adenosyl methionine does not restore microsomal function in rats with secondary biliary cirrhosis but improves transsulfuration. J Hepatol 16: S71.

124. Elsing C, Reichen J, Hurni B, Renner EL (1992). Hepatocellular Na/H exchange is activated in the rat four weeks after bile duct ligation. Hepatology 16: 119A.

125. Zimmermann H, Gerber B, Marti U, Reichen J (1992). Epidermal growth factor receptor expression on ductular epithelia in secondary biliary cirrhosis in the rat. Hepatology 16: 137A.

126. Krähenbühl S, Talos C, Reichen J (1992). Mitochondrial toxicity of hydrophobic bile acids and partial reversal by ursodeoxycholate. Hepatology 16: 156A.

127. Dällenbach A, Elsing C, Renner EL, Reichen J, Hurni B, Marti U (1993). Regulation of rat hepatocyte Na/H-antiporter at the mRNA level in biliary cirrhosis, but not after partial hepatectomy. Experientia 49: A48.

128. Widler P, Fisch HU, Schoch P, Zimmermann A, Reichen J (1993). Benzodiazepine receptor ligand activity is increased in rats with hepatic encephalopathy only after diazepam p.o. Experientia 49: A89.

129. Zimmermann H, Felley M, Zimmermann A, Reichen J (1993). Ito cells and reversibility of biliary cirrhosis in the rat. J. Hepatol. 18:S44.

130. Dällenbach A, Elsing C, Marti U, Reichen J, Renner EL (1993). Differential regulation of Na+/H+ antiport at the mRNA level in rat hepatocyte prolifertion induced by biliary cirrhosis and partial hepatectomy. J Hepatol 18:S47.

131. Zimmermann H, Ganz P, Zimmermann A, Oguey D, Marti U, Reichen J (1993). Liver regeneration in secondary biliary cirrhosis: Expression of proliferating nuclear antigen. J. Hepatol. 18:S65.

132. Lebbe C, Meijer DKF, Groothuis GMM, Franssen EJF, Sägesser H, Reichen J (1993). Protection against acute liver necrosis by naproxen targeted to non-parenchymal cells. J. Hepatol. 18:S73.

133. Zimmermann H, Ganz P, Zimmermann A, Oguey,D, Marti U, Reichen J (1993). Proliferation of hepatocytes in secondary biliary cirrhosis: Is there a relationship between nuclear EGF receptor and expression of proliferating nuclear antigen? Hepatology 18:160A..

134. Reichen J, Zhao D, Zimmermann A (1993). Myofibroblasts in cirrhotic rat liver: Bimodal distribution and relationship with sinusoidal capillarization. Hepatology 18: 207A.

135. Krähenbühl S, Talos C, Reichen J (1994). Ursodeoxycholate decreases mitochondrial toxicity of lipophilic bile acids. Hepatology 19: 86I.

136. Lebbe C, Meijer DKF, Groothuis GMM, Franssen EJF, Sägesser H, Talos C, Reichen J (1994). Naproxen targetted to hepatic nonparenchymal cells protects against liver damage induced by corynebacterium parvum-endotoxin. Hepatology 19:89I.

137. Reichen J, Zhao D, Zimmermann A (1994). Myofibroblasts are the main determinant of sinusoidal capillariation in cirrhotic rats. Hepatology 19:117I.

138. Zimmermann H, Hugi A, Reichen J (1994). The effect of increasing bile duct stenosis on hepatic structure in the rat. Hepatology 19:144I.

139. Reichen J, Sägesser H (1994). The effect of endothelin on microvascular exchange in rat liver: Reversible capillarization by closure of endothelial fenestrae. J. Hepatol. 21: S8.

140. Reichen J, Sägesser H, Gerbes AL (1994). Bosentan, an endothelin antagonist, lowers portal pressure in biliary cirrhotic rats: Evidence for a role of endothelin in portal hypertension. J. Hepatol. 21: S46.

141. Renner EL, Seiler C, Reichen J, Czerniak A (1994). Acute rejection episodes do not affect late graft function after orthotopic liver transplantation in man. J. Hepatol. 21: S88.

142. Reichen J, Sägesser H (1994). Endothelin inhibits microvascular exchange and endothelin antagonists improve microvascular exchange more in cirrhotic than in normal liver. Hepatology 20: 202A.

143. Zimmermann H, Sägesser H, Reichen J (1995). The effect of inhibtion of nitric oxide synthase (NOS) on hepatic compliance and microvascular exchange in cirrhotic rats. J Hepatol. 23 (S1): 73.

144. Meyer-Wyss B, Lavanchy D, Dolivo N, Gonvers JJ, Lauterburg BH, Mayerat C, Meier R, Miazza B, Renner EL, Reichen J, Wirth HP, Zala G (1995). Early respnse to interferon alfa-2b in patients with chronic hepatitis C depends on HCV genotype rather than viral load. J Hepatol. 23 (S1): 107.

145. Kurzen P, Zimmermann H, Marti U, Reichen J (1995). Decreased endothelial inducible nitric oxide synthase (eNOS) expression in hepatocytes of secondary biliary cirrhosis in the rat. J Hepatol. 23 (S1): 116.

146. Forestier M, Reichen J, Solioz M (1995). Application of mRNA differential display to cirrhosis in the rat: Fetuin is differentially expressed in biliary and micronodular cirrhosis. J Hepatol. 23 (S1):: 150.

147. Gerbes AL, Gülberg V, Sägesser H, Reichen J (1995). Circulating endothelin (ET)-1 and ET-3 in experimental cirrhosis: Relation to renal sodium handling but not to renal extraction of ET nor liver function. Hepatology 22: 164A.

148. Zimmermann H, Kurzen P, Marti U, Reichen J (1995). Nitric oxide synthase activity is decreased and its acinar distribution lost in the liver in secondary biliary cirrhosis in the rat. Hepatology 22: 258A.

149. Reichen J, Steiner M, Sägesser H, Gerbes AL (1995). Plasma endothelin-1 levels in cirrhosis in the rat are elevated and related to microsomal function. Hepatology 22: 259A.

150. Reichen J, Bustos-Castillo M, Berchtold M, Celio MR (1996). Hemodynamic effects of endothelin 1 in transgenic mice overexpressing parvalbumin in sinusoidal endothelial cells. J. Hepatol. 25 (Suppl 1): 67.

151. Stähelin B.J., Marti U, Zimmermann H, Reichen J (1996). The balance of BAX and Bcl-2 regulates apoptosis in biliary epithelial cells. J. Hepatol. 25 (Suppl 1): 67.

152. Klossner W, Zimmermann H, Sägesser H, Reichen J (1996). Bile duct ligation induces portal hypertension via decreased hepatic nitric oxide synthase prior to formation of biliary cirrhosis in rats. J. Hepatol. 25 (Suppl 1): 90.

153. Forestier M, Izbeki F, Talos C, Solioz M, Reichen J, Krähenbühl S (1996). Post-translational impairment of mitochondrial protein synthesis and mitochondrial proliferation in biliary cirrhosis in the rat. J. Hepatol. 25 (Suppl 1): 108.

154. Krähenbühl L, Talos C, Reichen J, Krähenbühl S (1996). Benzoate metabolism reflects hepatic mitochondrial function in vivo and in vitro in rats with long-term cholestasis. J. Hepatol. 25 (Suppl 1): 109.

155. Forestier M, Reichen J, Solioz M (1996). Identification of differentially expressed genes in liver cirrhosis in the rat. J. Hepatol. 25 (Suppl 1): 123.

156. Albrecht C, Meijer DKF, Sägesser H, Reichen J (1996). Naproxen targeted to endothelial and Kupffer cells protects against endotoxin in biliary cirrhosis in the rat. J. Hepatol. 25 (Suppl 1): 130.

157. Krähenbühl S, Krähenbühl L, Reichen J (1996). The hepatic mitochondrial coenzyme A pool is maintained and functionally intact in rats with long-term cholestasis. Hepatology 24: 140A..

158. Albrecht C, Meijer DKF, Sägesser H, Reichen J (1996). Targeting naproxen to endothelial and Kupffer cells protects against endotoxin in biliary cirrhosis in vivo. Hepatology 24: 187A.

159. Klossner W, Zimmermann H, Marti U, Sägesser H, Reichen J (1996. Portal pressure: A major determinant of hyperdynamic circulation in secondary biliary cirrhosis in the rat. Hepatology 24: 313A.

160. Stähelin B, Marti U, Solioz M, Zimmermann H, Reichen J (1996). False positive staining in TUNEL assay is due to release of endogeneous DNAse and inhibited by diethyl-pyrocarbonate in liver tissue. Hepatology 24: 368A.

161. Henz S, Reichen J, Liechti-Gallati S (1997). HLA-H gene mutations and hemochromatosis: The likely association of H63D with mild phenotype and the detection of S65C, a novel variant in exon 2. J. Hepatol 26 (Suppl 1): 57.

162. Zimmermann H, Renner EL, Reichen J (1997). Nitric oxide inhibits endothelin-1 induced contraction of hepatic stellate cells (Ito cells) in bile duct ligated livers in the rat. J. Hepatol 26 (Suppl 1): 94.

163. Van de Casteele M, Hösli M, Sägesser H, Reichen J (1997): Intraportal nitroprusside (NP) or glyceryl trinitrate (GNT) lower portal pressure by systemic effects in experimental cirrhosis. J. Hepatol 26 (Suppl 1): 96.

164. Bissig KD, Marti U, Solioz M, Forestier M, Zimmermann H, Lüthi M, Reichen J (1997). Epidermal growth factor (EGF) is decreased in rats with biliary cirrhosis but does not act as a paracrine growth factor after hepatectomy. J. Hepatol 26 (Suppl 1): 143.

165. van de Casteele M, Reichen J (1997). Hepatic NO synthase (NOS) is decreased in cirrhotic rats and correlates with hepatic functional impairment. Hepatology 26: 280A.

166. Albrecht C, Lüthi M, Forestier M, Reichen J (1997). Expression of COX1 and COX2 in biliary cirrhosis in the rat. Hepatology 26: 333A.

167. Flück M, Zimmermann H, Sägesser H, Hösli M, Reichen J (1997). Is liver innervation more important than nitric oxide in intrahepatic hemodynamics in normal and cirrhotic rats? Hepatology 26: 360A.

168. Diamantis I, van de Casteele M, Hurni B, Reichen J (1997). Detection of endothelin-1 and its receptors in rat liver endothelial cells by reverse transcriptase in situ polymerase chain reaction. Hepatology 26: 391A.

169. Flück M, van de Casteele M, Klossner W, Sägesser H, Zimmermann H, Reichen J (1998). Sinusoidal but not prehepatic portal hypertension is associated with decreased NO synthase activity. J. Hepatol. 28 (Suppl. 1): 76.

170. De Gottardi A, Shaw S, Boden J, Hösli M, Reichen J (1998): Organ specific expression of endothelin 1 in biliary cirrhosis in the rat. J. Hepatol. 28 (Suppl. 1): 76.

171. Albrecht C, Lüthi M, Reichen J (1998): Enhanced expression of 5-lipoxygenase in biliary cirrhosis in the rat. J. Hepatol. 28 (Suppl. 1): 85.

172. Forestier M, Bänninger R, Reichen J, Solioz M (1998). Differentially expressed genes in cirrhosis: Betaine - homocysteine methyltransferase is reduced in bile duct ligated rat liver. J. Hepatol. 28 (Suppl. 1): 86.

173. Diamantis I, Luethi M, Hoesli M, Reichen J (1998). Cloning of the rat ADAMTS1 gene: ADAMTS1 is down regulated in liver endothelial cells in cirrhosis. Hepatology 28: 344A.

174. Flück M, Zimmermann H, Shaw S, Zosse A, Hösli M, Reichen J (1998). Nitrate determination by HPLC in vessel and organ tissues of cirrhotic rats reflects alterations of local NOS activity. Hepatology 28: 461A.

175. De Gottardi A, Shaw S, Boden J, Hösli M, Reichen J (1998). Vascular endothelin 1 increases selectively in the prestenotic area in portal vein ligation in the rat. Hepatology 28: 461A.

176. Grabscheid B, Moradpour D, Kammer A, Reichen J, Houghton M, Blum HE, Cerny A (1998). Differential activation of CTL effector functions in chronic hepatitis C by MHC class I loaded endogeneously and exogenously. Hepatology 28: 466A.

177. De Gottardi A, Shaw S, Sägesser H, Reichen J (1999). Type A, but not type B endothelin receptor antagonists cause a significant decrease of portal pressure in the rat. Hepatogastroenterology 46: 1447.

178. Renner-Schneiter EC, Dufour JF, Fried R, Gonvers JJ, Knoblauch M, Malé PJ, Negro F, Reichen J, Rohner C, Steuerwald M, Renner EL (1999). The combination of daily interferon-a induction dosing and ribavirin in IFN nonresponders with chronic hepatitis C: Initial response and tolerability. Hepatology 30: 201A.

179. Redaelli C, Dufour JF, Schilling M, Büchler M, Reichen J (1999). Preoperative galactose elimination capacity predicts long-term survival after hepatic resection. Hepatology 20: 213A.

180. Koshy A, Bohler D, De Gottardi A, Sägesser H, Reichen J (2000). Sensitivity to endothelin 1 is decreased in ecNO synthase knockout mice associated with downregulation of ETA receptors. J. Hepatol. 32 (Suppl. 2): 28.

181. Zeuzem S, Feinman SV, Rasenack J, Heathcote EJ, Lay MY, Gane E, O'Grady J, Reichen J, Brunda MJ (2000). Evaluation of the safety and efficacy of once weekly PEG/Interferon alfa-2A for chronic hepatitis C. A multinational, randomized study. J. Hepatol. 32 (Suppl. 2): 29.

182. De Gottardi A, Tièche S, Kappeler A, Shaw S, Sägesser H, Zimmermann A, Reichen J (2000). Overexpression of endothelin 1 directly correlates with activation of hepatic stellate cells and portal pressure in bile duct ligated rats. J. Hepatol. 32 (Suppl. 2): 41.

183. De Gottard A, Shaw S, Dashwood M, Ledermann M, Reichen J (2000). Autoradiographic distribution and selective regulation of hepatic endothelin receptor subtypes in experimental cirrhosis. J. Hepatol. 32 (Suppl. 2): 62.

184. Renner-Schneiter EC, Dufour JF, Fried R, Gonvers JJ, Knoblauch M, Malè PJ, Negro F, Reichen J, Rohner C, Steuerwald M, Renner EL (2000). Interferon-a induction dosing and ribavirin in interferon non-responders with chronic hepatitis C: Interim analysis of an ongoing study. J. Hepatol. 32 (Suppl. 2): 104.

185. Schäfer M, Sägesser H, Reichen J, Krähenbühl L (2000). Portal and liver hemodynamic changes in rats during laparoscopy. J. Hepatol. 32 (Suppl. 2): 223.

186. Popescu A, Reichen J, Shaw S (2001). The citrulline assay does not measure nitric oxide synthase activity in the liver. J Hepatol 34 (Suppl 1): 56.

187. Biecker E, Sägesser H, Neef M, Sauerbruch T, Reichen J (2002). The cannabinoid receptor CB1 compensates for deficient eNOS activity in ecNOS knock-out mice and is markedly upregulated in murine and human cirrhosis. J Hepatol 36 (Suppl 1): 12.

188. Biecker E, Sägesser H, Shaw S, Reichen J (2002). NOS-1 compensates for NOS-3 deficiency in NOS-3 knockout mice and is upregulated in cirrhosis. J Hepatol 36 (Suppl 1): 45.

189. De Gottardi A, Unternährer M, Sägesser H, Ledermann M, Reichen J (2002). Sirolimus but not losartan significantly reduces liver fibrosis and mortality in bile duct ligated rats. J Hepatol 36 (Suppl 1): 49.

190. Popescu A, Reichen J, Shaw S (2002). Bile acids stimulate adrenomedullin production in rat aorta: A novel mechanism contributing to hyperdynamic circulation in portal hypertension. J Hepatol 36 (Suppl 1): 61.

191. Dufour JF, Zimmermann M, Reichen J (2002). Severe autoimmune hepatitis in patients with previous spontaneous recovery of a flare. J Hepatol 36 (Suppl 1): 152.

192. Russmann S, Decosterd L, Buclin T, Schwaar T, Baumann S, Brunner-Ferber F. Rosenkranz B, Knolle J, Reichen J (2004). The bradykinin antagonist icatibant increases electrolyte and water excretion after sodium challenge in patients with liver cirrhosis. Clin Pharm Ther 75: P12.

193. Poynard T, Schiff E, Terg R, Goncales F, Diago M, Reichen J, Moreno R, Bedossa P, Burroughs M, Albrecht J (2005). Sustained virologic response in the Epic3 trial. J Hepatol 42 (Suppl 2): 40.

194. Neef M, Ledermann M, Sägesser H, Schneider V, Reichen J (2005). Oral imatinib treatment decelerates early fibrogenesis but does not progression fo cirrhosis in bile duct ligated rats. J Hepatol 42 (Suppl 2): 72.

195. Terg R, Schiff E, Moreno R, Flamm S, Diago M, Reichen J, Heathcote J et al. (2005). Fibrosis stage is not a predeterminant of significant adverse events in previous interferon-ribavirin treatment falures receiving peg-interferona-2b/ribavirin weight-based dosing: Results from the EPIC3 program. Hepatology 42 (Suppl1): 530A.

196. Schiff E, Terg R, Uduando B, Moreno R, Flamm S, Diago M, Reichen J et al. (2005). Interferon induced thrombocytopenia is independent of level of fibrosis in patients with chronic hepatitis C: Results from the EPIC3 program. Hepatology 42 (Suppl. 1). 5331A.

197. Veldt BJ, Chen W, Hofmann P, Heathcote EJ, Wedemeier H, Reichen J et al. (2006). Increased risk of hepatocellular carcinoma among patients with hepatitis C cirrhosis and diabetes mellitus. Hepatology 44 (Suppl 1): 273A.

198. Neef M, Ledermann M, Sägesser H, Schneider V, Shaw S, Reichen J (2006). Whole genome analysis identifies connective tissue growth factor as a modulator of the antifibrotic effectivenss of long-term mTOR inhibition in bile duct-ligated rats. Hepatology 44 (Suppl 1). 582A.

199. Poynard T, Schiff E, Terg R, Moreno Otero R, Flamm S, Schmidt W, Berg T, Goncales F, Heathcote J, Diago M, McGarritty T, Maieron A, Reichen J et al. (2006). HCV RNA negativity afer 12 weeks of therapy is the best predictor or sustained viral response in the re-treatment of previous interfern-a/ribavirin non-responders: Results from the EPIC3 program. Hepatology 44 (Suppl 1): 606A.

200. Idrissivo L, Ledermann M, Sägesser H, Schneider V, Kuhn A, Shaw S, Reichen J, Neef M (2006). RAS/MEK/ERK and TGF-beta/CTGF pathway as possible determinants of resistance to rapamycin treatment in BDL-induced liver fibrosis. Results of gene array analysis. J Hepatol 46 (Suppl1): S129.